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SUMMARY 
As the vast majority of human cancers, hexavalent chromium [Cr(VI)] induced lung 
cancers (LC) are carcinomas that arise from epithelial cells. Though there is little doubt that 
multiple genetic alterations are necessary for epithelial cells malignant transformation to take 
place, several lines of evidence suggest that the progress towards full malignancy, of cells that 
bear potentially oncogenic mutations, requires a permissive tissue microenvironment. 
Therefore, to obtain reliable information on the mechanisms underlying the onset and 
progression of cancer a system resembling the in vivo epithelium is needed. In the case of LC 
such a system requires the use of normal human bronchial epithelial cells (NBEC). However, 
NBEC proliferate poorly and most epithelial cells quickly lose their differentiated features in 
vitro, probably because appropriate signals from extracellular matrix, growth factors and 
hormones have not been fully defined. The number of cultures that can be initiated is 
therefore limited by the yield of NBEC obtained from tissues or commercially available sources. 
Recently, however, it was established a new cultivation method in which epithelial cells 
and fibroblasts co-evolve together, which can be used to study the role of fibroblasts, the 
major stroma component intimately involved in tissue homeostasis, on epithelial cells 
malignant transformation. 
Fibroblasts portray a wide range of molecular, biochemical and morphological features 
which allow them to adapt to normal and pathological situations. Factors secreted by 
senescent fibroblasts (SF) can stimulate epithelial cells proliferation and disrupt epithelial 
differentiation, which may explain age-related cancers. 
The main targets of Cr(VI)-toxicity are bronchial epithelial cells (BEC) and bronchial 
fibroblasts. Although, Cr(VI) is known to induce senescence in human foreskin fibroblasts, it’s 
unkown whether Cr(VI) also induces senescence in human bronchial fibroblasts and the role of 
this senescent fibroblasts on bronchial epithelial cells malignant transformation. 
This dissertation describes the impact of Cr(VI)-expoure regimens on normal bronchial 
fibroblasts phenotype and the effects of the Cr(VI)-induced senescent fibroblasts on SV-40 
immortalised human bronchial epithelial cells phenotype using a co-culture method. 
To fullfill the objective of this dissertation several cultures of normal bronchial fibroblasts 
and normal bronchial epithelial cells were established out of lung biopsies. Thereafter, it was 
possible to established which Cr(VI)-exposure regimen was inducing a stable senescent 
XVI 
 
phenotype on human bronchial fibroblasts. Finally, co-cultures of bronchial fibroblasts both 
normal and Cr(VI)-senescent were cultured together with bronchial epithelial cells. These co-
cultures allowed the evaluation of how normal and senescent fibroblasts and epithelial cells 
co-evolved together in presence and absence of Cr(VI). 
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RESUMO 
O cancro de pulmão (CP) induzido por crómio hexavalente [Cr(VI)] emerge em células 
epiteliais sendo, por este motivo, designado carcinoma. Muito embora a ocorrência de 
múltiplas alterações genéticas seja um factor crucial na malignização de células recentemente, 
verificou-se que o processo requer a existência de um microambiente permissivo em torno das 
células com potenciais mutações oncogénicas. Por isso, a obtenção in vitro de dados precisos 
sobre os mecanismos subjacentes ao aparecimento e desenvolvimento da patologia maligna 
necessita, no caso do CP, de utilizar modelos que tenham características semelhantes ao 
epitélio bronquial humano. É um facto que células normais do epitélio bronquial humano 
(NBEC) terão de ser usadas, o que é muito limitativo dado que estas células, in vitro, se tornam 
indiferenciadas devido, possivelmente, à ausência de factores de crescimento e hormonas 
provenientes da matrix. Por isso, o uso de culturas primárias de NBEC, obtidas comercialmente 
ou de tecidos, é muito restrito. 
Recentemente foi implementada uma nova metodologia que permite cultivar células 
epiteliais conjuntamente com fibroblastos e, consequentemente, estudar o papel dos 
fibroblastos, o maior componente do estroma envolvido na homeostasia dos tecidos, na 
transformação maligna de células epiteliais. 
Os fibroblastos apresentam características moleculares, bioquímicas e morfológicas que 
favorecem a sua adaptação a situações normais e patológicas. É já do conhecimento que os 
factores segregados por fibroblastos senescentes (SF) têm capacidade para estimular a 
proliferação de células epiteliais, interferindo com a diferenciação celular e potenciando o 
eclodir de cancro em idosos. 
Os principais alvos de toxicidade de Cr(VI) são células epiteliais bronquiais e fibroblastos 
bronquiais. Apesar de se saber que Cr(VI) é capaz de induzir senescência em fibroblastos do 
prepúcio, desconhece-se se o Cr(VI) também induz senescência em fibroblastos bronquiais 
humanos e o papel deste fibroblastos senescentes na transformação maligna de células 
epiteliais bronquiais. 
Esta dissertação descreve o estudo realizado tendo em vista avaliar se o Cr(VI) induzia o 
desenvolvimento do fenótipo senescente  em fibroblastos bronquiais normais, e o efeito da 
senescência em fibroblastos no fenótipo de células epiteliais bronquais normais, imortalizadas 
por SV-40, usando um método de co-cultura. 
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Para cumprir os objectivos desta dissertação diversas culturas de fibroblastos bronquiais 
normais e células epiteliais bronquiais normais foram estabelecidas a partir de biopsias de 
pulmão. Posteriormente, foi possível determinar qual o regime de exposição a Cr(VI) induzia 
um fenótipo senescnte estável em fibroblastos bronquais humanos. Finalmente, co-culturas de 
fibroblastos bronquiais, tanto normais como senescentes devido a Cr(VI), e células epiteliais 
bronquiais foram realizadas. Estas co-culturas permitiram a avaliação de como fibroblastos, 
normais e senescentes, e células epiteliais co-evoluiam em conjunto, na presence e ausência 
de Cr(VI). 
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1.1. THE RESPIRATORY SYSTEM   
 In humans and other mammals the respiratory system is essentially composed by the 
airways, the lungs and the respiratory musculature. The bronchial airways, also called the 
bronchial tree, besides conducting the air to and from the lungs, also account for its 
conditioning, warming and humidification. In the alveolar regions of the lungs, the oxygen and 
the carbon dioxide passively diffuse between the conditioned air and the outside atmosphere 
a process called pulmonary haematosis [Junqueira and Carneiro, 2008]. 
The two primary bronchi are originated from a bifurcation of the terminal part of the 
trachea. These cartilaginous structures penetrate each lung at the hilum, where they subdivide 
into secondary, tertiary and smaller bronchi, forming a tree-like structure called 
bronchopulmonary segment. This structure has its own connective tissue capsule and blood 
supply and represents 10–12% of each lung. The existence of such lung segments facilitates 
the specific surgical resection of unhealthy lung tissue without affecting nearby healthy tissue, 
being of most interest for our work. 
 As the number of segments multiplies, becoming smaller, each bronchus reaches a 
diameter of approximately 5 mm. In this region of the respiratory system the lung tissue forms 
a pseudostratified epithelium with ciliated cells interspersed with goblet cells. This entire 
cellular complex is supported by a thin lamina propria of smooth muscle, elastic fibres and 
connective tissue that also functions as a feeder layer to the epithelium [Junqueira and 
Carneiro, 2008]. 
Figure 1.1: Representation of different cell types 
present throughout the airway epithelium 
(adapted from BeruBé et al., 2010). 
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1.2. THE BRONCHIAL EPITHELIUM 
The bronchial epithelium is characterized by the aggregation of polyhedral epithelial 
cells that produce a small amount of extracellular matrix [Junqueira and Carneiro, 2008]. The 
characteristic shape of these cells results from their close juxtaposition in cellular layers, and is 
similar to what would be observed if a large number of inflated balloons were compressed into 
a limited space. The strong intercellular adhesion observed in these cells allows the formation 
of large cellular layers that cover all the body surfaces and cavities. Their protective and 
contractile features allow the simultaneous absorption and secretion of molecules inside and 
outside the organs. Additionally, in certain cases like in the olfactory epithelium, some 
specialized cells act as sensory cells.  
The nuclei of bronchial epithelial cells are spherical, a characteristic of cuboidal cells, and 
their long axis are always parallel to the main axis of the cell [Junqueira and Carneiro, 2008]. 
The nuclei can be localized at different levels within the cell, giving the false appearance of 
cellular stratification [Junqueira and Carneiro, 2008]. As the lipid-rich membranes between 
cells are frequently indistinguishable under the light microscope, stained cells’ nuclei are 
frequently used to infer the shape and number of cells.  
Human bronchial epithelial cells (HBEC) generally show polarity, with organelles and 
membrane proteins distributed unevenly in different parts of the cell [Junqueira and Carneiro, 
2008]. The region of the cell that faces the connective tissue is called the basal pole, whereas 
the opposite pole, usually facing a respiratory cavity, is the apical pole. The intervening sides 
apposed in neighbouring cells are called the lateral surfaces [Junqueira and Carneiro, 2008]. 
The membranes on the lateral surfaces of adjoining cells often have numerous infoldings to 
increase the contact area and these cells’ functional capacity. The different regions of 
polarized cells may have different functions. 
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Figure 1.2: Image of bronchial epithelium, primarily columnar cells with cilia (arrows), with fewer goblet cells. The 
lamina propria has both smooth muscle (SM) and small serous glands (G) near cartilage (C) (adapted from 
Junqueira and Carneiro, 2008). 
 
The lateral membranes of epithelial cells also exhibit several specialized intercellular 
junctions. These junctions can function as seals, preventing the flow of materials between the 
cells (occluding junctions), sites of adhesion (adhesive or anchoring junctions) or channels for 
communication between adjacent cells (gap junctions) (Figure 1.3). 
 
 
 
 
 
 
 
 
 
Figure 1.3: Intercellular communication in the lung through gap junctions (adapted from Johnson and Koval, 2009). 
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HBEC have elongated (5–10 m long and 0.2 m diameter), high motile cilia on their apical 
surface. Each cilium is bounded to the cell membrane by the basal bodies and contains at the 
base an axoneme with a central pair of microtubules surrounded by nine peripheral 
microtubule pairs [Junqueira and Carneiro, 2008]. Cilia are electron-dense structures localized 
at the apical pole, just below the cellular membrane, exhibiting coordinated rapid back-and-
forth movements to propel a current of fluid and suspended matter in one direction over the 
ciliated epithelium [Junqueira and Carneiro, 2008]. This movement depends upon the 
hydrolysis of the adenosine triphosphate (ATP) bounded to the ciliary dynein present on the 
peripheral microtubule doublets of the axoneme. Each ciliated cell of the trachea is estimated 
to have about 250 cilia. [Junqueira and Carneiro, 2008]. 
The HBEC can cover up to 221 to 223 branches of the respiratory zone. However, they only 
cover 1% of the whole respiratory surface [BéruBé et al., 2010]. These cells have an essential 
role in the maintenance of the respiratory capacity, being able to work as an alveolar defence 
against several pathogenic agents, for example, by keeping the mucosa secretion levels. 
Therefore, the HBEC have a critical role in respiratory disorders, such as asthma and lung 
cancer [Crystal, Randell, Engelhardt, et al., 2008]. 
Because the bronchial epithelium is directly exposed to a wide range of injurious agents, 
HBEC are very susceptible to pro-inflammatory signals that easily modulate their function 
[Crystal, Randell, Engelhardt, et al., 2008]. In addition, the multiplicity of microenvironments 
throughout the respiratory tract, by inducing different levels of cellular differentiation, renders 
HBEC to adopt rather diverse cellular phenotypes. For instance, HBEC able to produce 
secretoglobin, glycoprotein capable of cell adhesion (cluster of differentiation molecule CD34) 
and surfactant protein-C (SP-C) are able to proliferate easily in response to tissue wounds 
[Crystal, Randell, Engelhardt, et al., 2008]. 
Bronchial epithelial cells can easily go into mitosis, although this renewal process varies 
accordingly to the tissue. Growth factors, such as hepatocyte growth factor (HGF), insulin 
growth factor-1 (IGF-1) and fibroblast growth factor-7 and 10 (FGF-7; FGF-10) [Skibinski et al., 
2007; Lebeche et al., 1999], as well as collagen type IV [Freshney, 2002], induce HBECs’ 
proliferation, while differentiation depend on thyroid transcription factor-1 (TITF-1), forkhead 
orthologs protein family (FOX) and β-Cadherin, following interaction with several transcript 
factors [Maeda, Davé, Whitsett, 2007].  
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Myoepithelial cells are found in the glandular epithelium as a thin layer above the 
basement membrane but, generally, beneath the luminal cells. In the mammary gland 
myoepithelial cells constitute the basal cell layer of an epithelium that harbours the epithelial 
progenitor/stem cells [Freshney, 2004; Ghajar and Bissell, 2008]. Easily distinguished from 
epithelial cells, that just express keratins, myoepithelial cells express simultaneously keratins 
and alpha smooth muscle actin (α- SMA) [Berman, 2009]. In wound healing, myoepithelial cells 
reactively proliferate, and their presence in a hyperplastic tissue usually suggests absence of 
cancer. Only rare cancers, like adenoid cystic carcinomas, contain myoepithelial cells as one of 
their malignant components [Berman, 2009]. 
Figure 1.4: K8 (green), an epithelial marker, stains throughout mammary structures while K14 (red), indicative of 
myoepithelial cells in vivo, is confined to the basal surface (* denotes lumen) (adapted from Ghajar and Bissell, 
2008). 
 
 
1.3. THE CONNECTIVE TISSUE AND THE EXTRACELLULAR MATRIX 
The connective tissue has a central role in the human body because it is responsible, as 
its name suggests, for connecting and supporting all the other tissues of the body.  Fibroblasts 
are a prominent component of this tissue that makes up the stromal compartment [Olumi et 
al., 1999]. They are originated from undifferentiated mesenchymal cells and they orchestrate 
the crosstalk between the stroma and the epithelial cells, driving to tissue homeostasis 
[Junqueira and Carneiro, 2008; Olumi et al., 1999]. 
In connective tissue are found: cells, fibers, and ground substance. Fibroblasts are 
prominent cells of the connective tissue that makes up the stromal compartment [Olumi et al., 
1999]. These cells are originated from undifferentiated mesenchymal cells and orchestrate the 
crosstalk between the stroma and the epithelial cells, driving to tissue homeostasis [Junqueira 
and Carneiro, 2008; Olumi et al., 1999]. During the connective tissue’ formation, fibroblasts 
synthesize collagen, elastin, glycosaminoglycans, proteoglycans and multiadhesive 
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glycoproteins, building up the ECM. Subsequently, a wide combination of protein fibers 
(collagen and elastic fibers) forms and creates the so called ground substance. This highly 
hydrophilic viscous complex of anionic substances stabilizes the ECM by binding it to receptor 
proteins, integrins, on the surface of cells and to the other matrix components [Junqueira and 
Carneiro, 2008].  
In addition to its major structural role, ECM is a reservoir of factors controlling cell growth 
and differentiation [Junqueira and Carneiro, 2008], and the hydrophilic nature of the majority 
of the connective tissue provides the medium through which nutrients and metabolic wastes 
are exchanged between cells and their blood supply [Junqueira and Carneiro, 2008].  
Figure 1.5: Electronic Microscopy image of ECM ultrastructure, showing ground substance, collagen (C); elastic 
fibers (E) and fibroblasts (F) (adapted from Junqueira and Carneiro, 2008). 
 
 
1.3.1. FIBROBLASTS 
Fibroblasts are important to epithelial function, particularly in the lung, more 
specifically in the bronchus, due to the predominance of a pseudostratified epithelial layer that 
is greatly dependent on a stable and rich connective tissue, being responsive to the presence 
of collagen, β-integrins and EGF for stability. Recent studies revealed that fibroblasts and 
epithelial cells cooperate in response to airway inflammation [Knight, 2001], and fibroblasts 
were also able to induce stress in lung epithelial cells in vitro [Bartling et al., 2006]. 
In human adults, the connective tissue’ fibroblasts rarely undergo division. Nevertheless, 
mitosis can resume whenever an organ requires additional fibroblasts as during the process of 
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wound healing [Junqueira and Carneiro, 2008]. In accordance, two stages of activity are often 
observed in fibroblasts: active and quiescent [Junqueira and Carneiro, 2008].  
Active fibroblasts are morphologically distinct from quiescent fibroblasts that are 
scattered within the matrix they have already synthesized. As a consequence, some 
histologists reserve the term fibroblast to denote the active cell and fibrocyte to designate the 
quiescent fibroblast [Junqueira and Carneiro, 2008]. Active fibroblasts typically display large 
active nuclei and an eosinophilic cytoplasm tapering off in both directions along the axis of the 
nucleus, morphology usually called "spindle-shaped”. In addition, these fibroblasts also have 
an abundant and irregularly branched cytoplasm [Junqueira and Carneiro, 2008]. Their nuclei 
are ovoid, large and pale-staining, with fine chromatin and a prominent nucleolus [Junqueira 
and Carneiro, 2008]. The cytoplasm is rich in rough endoplasmic reticulum (RER), and the Golgi 
apparatus is well developed [Junqueira and Carneiro, 2008]. Active fibroblasts are the targets 
of various growth factors that influence cell growth and differentiation, such as TGF-β, and 
Vascular Endothelial Growth Factor (VEGF) [Sugiura et al., 2007]. 
Quiescent fibroblasts are smaller than active fibroblasts. Usually spindle-shaped, they 
have a smaller and darker elongated nucleus and more acidophilic cytoplasm with much less 
RER [Junqueira and Carneiro, 2008]. 
Figure 1.6: Image of both active and quiescent fibroblasts from the dermis (adapted from Junqueira and Carneiro, 
2008). 
 
Myofibroblasts, a specific sub-population of fibroblasts, are found sub-epithelially in 
many mucosal surfaces, acting as a regulator of the shape but also as stem cells niche. They 
can be distinguished from fibroblasts because they express, in addition to vimentin, α-SMA. 
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Myofibroblasts have both support and paracrine functions. In wound healing they play a 
central role by depositing extracellular collagen fibers and wound contraction [Komuro, 1990]. 
They contain smooth muscle myosin isoforms in addition to α-SMA, the requisite machinery 
for contraction and/or motility, and respond to proinflammatory cytokines by producing 
matrix proteins and additional growth factors [Mori et al., 1992]. 
 
 
1.4. LUNG CANCER 
Although cancer has been known since the early Egypt, only in the latter 30 years it has 
been extensively studied [Knowles et al., 2005; Weber, 2007]. According to the literature, 
cancer can be characterized as a complex disease occurring as a result of a progressive 
accumulation of genetic and epigenetic alterations that enable cells’ escape from normal 
cellular and environmental controls [Mills, 2002]. Nowadays, cancer represents one of the 
trending causes of death [Knowles et al., 2005; Weber, 2007]. 
Lung cancer (LC) is the most frequent cause of cancer deaths in both men and women in 
industrialized countries [Cancer Research UK, 2011]. The highest rates of lung cancer are 
found in Central and Eastern Europe and in northern America [Cancer Research UK, 2011]. 
Within the European Union (EU-27) the countries with the highest male rates are Hungary and 
Poland and the ones with the lowest rates are Sweden and Cyprus [Cancer Research UK, 
2011]. In 2005, in the United States, the combined annual number of deaths from breast, 
colon and prostate cancer would not equal the death toll from lung cancer, and in 2004 more 
than 150,000 patients died of this disease [Spiro and Silvestri, 2005]. The lowest lung cancer 
rates are found in Middle African countries [Panno, 2005]. 
11 
 
Table 1.1: Resume of new cases and deaths for different types of cancer in the United States of America in 2003 
(adapted from Panno, 2005). 
 
Several environmental and industrial carcinogens like tobacco smoke, nickel, arsenic, 
chromium and polycyclic hydrocarbons have been accepted as major causes of LC [Coppé et 
al., 2008a; Salnikow and Zhitkovich, 2008; Urbano et al., 2008]. Non-ferrous metal production 
industry as well as painting and leather industries have been considered of high-risk to LC 
development. There is also evidence that heavy occupational exposure to diesel exhaust 
increases LC risk and the large American prospective Agricultural Health Study Exposure 
suggests that exposure to herbicides and insecticides also increases LC risk [Ruddon, 2007]. 
Occupational exposures to silica can result in silicosis, which represents an increased risk for LC 
[Cancer Research UK, 2011]. Finally, evidence supports an increased risk of LC development 
following exposures to asbestos in non-smokers as well as for recent smokers who also have 
previously worked with that material [Cancer Research UK, 2011]. 
LC susceptibility and risk are also increased in inherited cancer syndromes caused by rare 
germ-line mutations in Tp53, retinoblastoma (RB) and the epidermal growth factor receptor 
(EGFR) gene [Herbst, Heymach and Lippman, 2008]. More recently, three large genome wide 
association studies identified an association between single-nucleotide polymorphism (SNP) 
variation at 15q24–15q25.1 and a higher susceptibility to LC development [Herbst, Heymach 
and Lippman, 2008]. This newly identified LC-associated SNP variation region includes two 
genes encoding subunits of the nicotinic acetylcholine receptor alpha, which is regulated by 
nicotine exposure [Herbst, Heymach and Lippman, 2008]. 
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DNA repair capacity is also very important in what regards LC development. In 
agreement, germ-line alterations in nucleotide excision repair system genes, like ERCC1, 
increase LC susceptibility and risk [Herbst, Heymach and Lippman, 2008]. This scenario is 
worsened when accompanied by exposure to tobacco smoke [Herbst, Heymach and Lippman, 
2008].  Increased expression of DNA synthesis and repair genes, including RRM1 (the 
regulatory subunit of ribonucleotide reductase) and ERCC1, in non– small-cell LC correlates 
with a better overall prognosis but no benefit from platinum-based chemotherapy 
[Herbst, Heymach and Lippman, 2008]. 
Commonly documented LCs have an epithelial origin and, as a consequence, are classified 
as carcinomas [Panno, 2005]. Carcinomas are generally divided into two major types: small cell 
lung cancer (SCLC), which accounts for about 25% of all lung tumours, and non-small cell lung 
cancer (NSCLC), that accounts for about 75% of the total LCs [Freshney, 2004]. NSCLC can 
additionally be sub-divided in three major histological types:  squamous carcinoma, 
adenocarcinoma, and large cell carcinoma [Freshney, 2004]. 
 SCLC typically disseminates widely and is seldom cured by surgical resection, whereas 
NSCLC may be cured by surgery if diagnosed at early stages [Freshney, 2004]. In addition, SCLC 
tumours have a better initial response to cytotoxic therapies than do NSCLC. 
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Table 1.2: Genetic abnormalities related to non-small-cell lung cancer and small-cell lung cancer (adapted from 
Herbst, Heymach and Lippman, 2008). Non–small-cell lung cancer includes squamous-cell carcinoma and 
adenocarcinoma. Neuroendocrine fields have been detected only in tissue surrounding tumors and have been 
characterized by extremely high rates of allelic loss and by c-MET overexpression (Salgia R: personal 
communication). Variations are based in part on smoking profiles. The percentages include increased gene copy 
numbers from amplification or polysomy and represent percentages from resected cancers. The percentages are 
higher in primary tumors from patients with metastatic disease. Increased copy numbers have been reported in 
squamous dysplastic lesions but not in adenocarcinoma precursors. Genomic EGFR variant III mutations have been 
detected only in lung squamous-cell carcinoma, and these tumors are sensitive preclinically to irreversible EGFR 
tyrosine kinase inhibitors. The incidence of 5% is substantially lower than that of 30 to 40% for the detection in 
squamous-cell carcinoma or adenocarcinoma by immunohistochemical analysis or other techniques. The anaplastic 
lymphoma kinase (ALK) fusion gene (involving chromosome 2p), consisting of parts of EML4 and ALK, is 
transforming in fibroblasts and occurs in adenocarcinoma but not in other types of non–small-cell lung cancer or 
other non-lung cancers. 
 
 
1.4.1. GENOMIC HALLMARKS OF LUNG CARCINOMAS 
The first phase of carcinomas’ development, and as a consequence, of lung epithelium 
malignant transformation, is dysplasia. Dysplasia is characterized by a disordered growth of 
cells in a tissue or organ, accompanied by cell differentiation [Panno, 2005; Schulz, 2005]. 
EGFR amplification is commonly associated with this process, particularly in higher grades 
dysplasias, and is a renowned lung-cancer risk factor when detected in the sputum of smokers 
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[Herbst, Heymach and Lippman, 2008]. Gain of function of this receptor leads to the 
activation of several signalling pathways, such as the Ras–Raf–Mek, responsible for the growth 
of cancer cells and tumour progression (Figure 1.7). 
 
 
 
 
 
 
 
 
Figure 1.7: Some EGFR-dependent signaling Pathways. EGFR activates several major downstream signaling 
pathways, including Ras–Raf–Mek and the pathway consisting of phosphoinositide 3-kinase (PI3K), Akt, and 
mammalian target of rapamycin (mTOR), which in turn may have an effect on proliferation, survival, invasiveness, 
metastatic spread, and tumor angiogenesis through pathways that are either dependent on or independent of the 
hypoxia inducible factor (HIF). These pathways also may be modulated by other receptor tyrosine kinases, such as 
insulin-like growth factor 1 receptor (IGF-1R) and cMET, and by the LKB1–amp-activated protein kinase (AMPK) 
pathway, which is involved in energy sensing and cellular stress. Most of these functions depend on signaling 
through the kinase domain. However, kinase-independent functions, such as maintaining glucose transport, have 
been reported. TSC2 denotes tuberous sclerosis complex 2, and VEGF vascular endothelial growth factor (adapted 
from Herbst, Heymach and Lippman, 2008). 
 
Activating KRAS mutations are limited to NSCLC (predominantly adenocarcinomas), and 
mutually exclusive to mutations in the EGFR and HER2 kinase. They are associated with an 
increased resistance to EGFR inhibitors (tyrosine kinase inhibitors and cetuximab). KRAS 
mutations are chiefly smoking-related G→T transversions affecting the exon 12 (in 90% of 
patients) or exon 13 of the KRAS gene. A distinct KRAS mutational profile consisting of G→A 
transition mutations was recently detected in patients with adenocarcinoma who had never 
smoked [Herbst, Heymach and Lippman, 2008]. Nevertheless, its functional significance is 
unclear. KRAS mutations appear to be an early event (e.g., detectable in the pre-invasive 
lesions of atypical adenomatous hyperplasia and bronchoalveolar carcinoma) that precedes 
smoking-related lung adenocarcinoma. They are generally correlated with poor prognosis 
[Herbst, Heymach and Lippman, 2008]. Further evidence supporting this gene’s role in the 
pathogenesis of LC comes from transgenic mice that bear a mutated KRAS. These mice 
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developed multifocal atypical adenomatous hyperplasia and adenocarcinoma with early MET 
gene activation following KRAS-induced carcinogenesis [Herbst, Heymach and Lippman, 
2008]. 
BRAF mutations have also been detected in NSCLC and may be an early event in lung 
tumourigenesis [Herbst, Heymach and Lippman, 2008]. Additionally, transversions (smokers) 
and transitions (non-smokers) also have been reported for the Tp53 gene in lung 
adenocarcinoma [Herbst, Heymach and Lippman, 2008]. 
A recent SNP array screening in human lung adenocarcinoma samples identified a wide 
range of genomic amplifications, namely in regions containing the KRAS, MYC, VEGF genes and 
several cell-cycle-associated genes [Weir, 2007].  Nevertheless, the most common focal event 
in this high-resolution analysis was an amplification of the TITF1 (also called NKX2-1) gene at 
the 14q13.3 chromosomal region 14q13.3. TITF1 encodes a lineage-specific transcription factor 
that is essential for the formation of the cells lining the lung alveoli (type II pneumocytes). In 
vitro, transfection of immortalized normal human lung epithelial cells with at least two of the 
three genes (TITF1, NKX2-8, and PAX-9) in the 14q13.3 region caused increased growth 
potential of the cells, suggesting that these three genes may work cooperatively in the 
pathogenesis of LC [Herbst, Heymach and Lippman, 2008]. Recent data indicate that 
squamous-cell carcinoma also exhibits TITF1 amplification, as detected by fluorescence in situ 
hybridization (FISH). Yet, in contrast with adenocarcinoma, TITF1 protein levels are kept 
untouched [Herbst, Heymach and Lippman, 2008]. 
In its struggle to survive in the absence of nutrients and in the presence of accumulated 
metabolic by-products, tumours build up a new tumour-associated microvessel network 
following a process called angiogenic switch [Schulz, 2005]. VEGF is the main orchestrator of 
this process, as the increase in its levels, in pre-malignant bronchial epithelial cells, induces the 
progression from low grade to high grade bronchial dysplasia [Herbst, Heymach and Lippman, 
2008]. 
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Figure 1.8: Representation of the tumor development from a genetically altered cell to hyperplasia, dysplasia, in 
situ cancer (this case carcinoma) and invasive cancer (adapted from Weinberg, 1996). 
 
During the subsequent steps of malignant progression, namely hyperplasia, metaplasia, 
and carcinoma in situ (Figure 1.8), the intense angiogenic activity continues, allowing a 
correlation between the factors associated with increased tumour angiogenesis, namely VEGF, 
and the LC development to be established. As a consequence, circulating VEGF levels are used 
to predict the clinical benefit of using VEGF inhibitors in LC patients [Herbst, Heymach and 
Lippman, 2008]. Whenever positive results are expected, the VEGF monoclonal antibody 
bevacizumab is used in combination with standard chemotherapy to block angiogenesis and 
reduce the growing ability of NSCLC [Herbst, Heymach and Lippman, 2008].  
The PI3K/Akt and the mTOR, pathways (Figure 1.7) are also activated during early in lung 
carcinogenesis, even though Akt overexpression starts during bronchial dysplasia [Herbst, 
Heymach and Lippman, 2008]. Mutations or amplifications of PIK3CA, which encodes the PI3K 
catalytic subunit, are frequently found in a subgroup of NSCLC, especially the squamous-cell 
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carcinoma, and associate with increased PI3K activity and Akt expression [Herbst, Heymach 
and Lippman, 2008]. Inhibition of Akt was reported to induce apoptosis of human pre-
malignant and malignant lung cells and to prevent lung carcinogenesis in an animal model 
[Herbst, Heymach and Lippman, 2008]. mTOR inhibitors also blocked malignant progression of 
atypical adenomatous hyperplasia lesions in the KRAS mouse model [Herbst, Heymach and 
Lippman, 2008]. Since mTOR drives tumourigenesis in part through macrophages, the anti-
tumour effect of mTOR inhibition is mainly directed to the tumour microenvironment [Herbst, 
Heymach and Lippman, 2008]. 
 
 
1.4.2. THE INVASIVE PROPERTIES OF CARCINOMA CELLS  
As to the mechanisms underlying LC invasion and metastasis, they are largely an enigma. 
It is clear that, as carcinomas arising from epithelial tissues progressed to higher pathological 
grades of malignancy with local invasion and distant metastasis establishment, the associated 
cancer cells typically develop morphological changes and alter their attachment to neighbour 
cells and to the ECM [Parrinello et al., 2005; Hu and Polyak, 2008]. In the process of 
dissemination, the best characterized alteration is the loss, by the tumour epithelial cells, of E-
Cadherin, a key cell-to-cell adhesion molecule [Hanahan and Weinberg, 2011]. By forming 
adherent junctions in adjacent epithelial cells, E-Cadherin helps to assemble epithelial cell 
sheets and to maintain the proliferation arrest of the cells within these sheets, avoiding 
unregulated epithelial proliferation and hyperplasia. Increased expression of E-Cadherin is a 
well-established antagonist of invasion and metastasis, whereas the reduction of its expression 
is known to potentiate invasive and metastatic phenotypes [Hanahan and Weinberg, 2011]. 
The frequently observed down-regulation and occasional mutational inactivation of E-Cadherin 
in human carcinomas provided strong support for its role as a tumor suppressor [Hanahan 
and Weinberg, 2011]. 
A developmental regulatory program, referred to as the ‘‘epithelial-mesenchymal 
transition’’ (EMT), has become prominently implicated as a means by which transformed 
epithelial cells can acquire the ability to invade, to resist apoptosis and to disseminate 
[Hanahan and Weinberg, 2011]. By co-opting a process involved in various steps of embryonic 
morphogenesis and wound healing, carcinoma cells can concomitantly acquire multiple 
attributes that enable invasion and metastasis. This multifaceted EMT program can be 
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activated transiently or stably, and to differing degrees, by carcinoma cells during the course of 
invasion and metastasis [Hanahan and Weinberg, 2011]. 
A set of pleiotropic transcriptional factors, including Snail, Slug, Twist, and Zeb1/2, mostly 
identified by developmental genetics, orchestrate the EMT and EMT-related migratory 
processes during embryogenesis [Hanahan and Weinberg, 2011]. These transcriptional 
regulators are expressed in various combinations in a number of malignant tumour types, and 
have been shown in experimental models of carcinoma to be determinant for programming 
invasion and to elicit metastasis when ectopically overexpressed [Hanahan and Weinberg, 
2011]. Such transcription factors have been associated with the loss of adherent junctions 
[Hanahan and Weinberg, 2011], the conversion from a polygonal/epithelial to a 
spindly/fibroblastic morphology [Hanahan and Weinberg, 2011], the expression of matrix-
degrading enzymes [Hanahan and Weinberg, 2011], an increased motility and a heightened 
resistance to apoptosis [Hanahan and Weinberg, 2011], all traits implicated in the processes of 
invasion and metastasis. Several of these transcription factors can directly repress E-Cadherin 
gene expression, thereby depriving neoplastic epithelial cells of this key suppressor of motility 
and invasiveness [Hanahan and Weinberg, 2011]. 
An important factor during invasion and metastasis is the VEGF. The VEGF-A gene 
encodes ligands involved in orchestrating new blood vessel growth during embryonic and 
postnatal development, in homeostatic survival of endothelial cells and in physiological and 
pathological situations in the adult. VEGF signaling via three receptor tyrosine kinases (VEGFR-
1–3) is regulated at multiple levels, reflecting this complexity of purpose. Thus, VEGF gene 
expression can by upregulated both by hypoxia and by oncogene signaling [Hanahan 
and Weinberg, 2011], favouring tumour growth and dissemination. In addition, VEGF ligands 
can also be sequestered in the extracellular matrix in latent forms that are subject to release 
and activation by extracellular matrix-degrading proteases (e.g., MMP-9) [Hanahan 
and Weinberg, 2011]. Other pro-angiogenic signals, such as members of the fibroblast growth 
factor (FGF) family, have been implicated in sustaining tumour angiogenesis when their 
expression is chronically up-regulated [Hanahan and Weinberg, 2011]. Thrombospondin 1 
(TSP-1), a key counterbalance in the angiogenic switch, also binds transmembrane receptors 
displayed by endothelial cells and thereby evokes suppressive signals that can counteract pro-
angiogenic stimuli [Hanahan and Weinberg, 2011]. 
At the epithelium level, the formation of tumours requires loss of growth control, 
unlimited proliferation ability, resistance to apoptosis and finally, angiogenic ability to 
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potentiate the formation of metastasis [Krtolica and Campisi, 2002; Bissell et al., 2003]. In 
addition, malignant cells have to undergo changes in the expression of organizational proteins 
such as β1-integrins and/or β3-integrins [Bissell et al., 2003; Kenny and Bissell, 2003; Ghajar 
and Bissell, 2008], dystroglycan [Bissell et al., 2003; Kenny and Bissell, 2003; Ghajar and 
Bissell, 2008], TGF-β [Bissell et al., 2003; Ghajar and Bissell, 2008]  and the IL-6 or IL-8 
cytokines [Skibinski et al., 2007; Ghajar and Bissell, 2008].The expression of the EGF receptors 
(EGFR) is also frequently found up-regulated which, by triggering an EGF-mediated intracellular 
signal pathways response, allows tumour development [Bissell et al., 2003; Kenny and Bissell, 
2003; Bissell et al., 2005]. Finally, loss of function of tumour-suppressor genes such as Rb, the 
breast-cancer susceptibility proteins 1 and 2 (BRCA1 e BRCA2) and the cell-cycle checkpoint 
protein 2 homologous (CHK2), have been proved to contribute to the morphology changes 
associated with deregulated cell proliferation [Bissell et al., 2005]. 
During the invasion process, the ECM also suffers a tremendous remodelling, manly 
driven by its fibroblasts. Those fibroblasts are no longer normal; instead, during the 
malignization process of the epithelial cells, they underwent series of phenotypic and genomic 
alterations that transformed them and committed them to the tumour [Olumi et al., 1999]. 
These newly designated carcinoma-associated-fibroblasts (CAFs) have an abnormal migratory 
behaviour in vitro and an altered expression of growth factors such as platelet-derived growth 
factor, IGF-I and -II, TGF-β1, HGF/epithelial scatter factor, and keratinocyte growth factor 
[Olumi et al., 1999]. Nevertheless, although these phenotypic changes have been documented 
in CAFs, their impact on tumour growth and development has not yet been investigated 
[Olumi et al., 1999]. 
 
 
1.4.3 METABOLIC REPROGRAMMING OF CARCINOMA CELLS  
The existence of a metabolic switch in cancer cells has been proposed for decades [Hsu 
and Sabatini, 2008; Hanahan and Weinberg, 2011]]. Such reprogramming of energy 
metabolism is seemingly counterintuitive, as cancer cells must compensate for the 18-fold 
lower efficiency of ATP production afforded by glycolysis relative to mitochondrial oxidative 
phosphorylation. It is accomplished, in part, by up-regulating glucose transporters (GLUT), 
notably GLUT1, which substantially increases glucose cellular uptake [Hanahan and Weinberg, 
2011]. Indeed, markedly increased uptake and utilization of glucose have been documented in 
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many human tumour types, using positron emission tomography (PET) with a radiolabelled 
analogue of glucose (18F-fluorodeoxyglucose, FDG) as a reporter [Hanahan and Weinberg, 
2011]. Glycolytic fuelling has been shown to be associated with activated oncogenes (e.g., RAS, 
MYC) and mutant tumour suppressors (e.g., TP53), whose changes in tumour cells have been 
selected, primarily, for their benefits in conferring the hallmark capabilities of cells’ 
proliferation, avoidance of cytostatic controls, and attenuated of apoptosis. This reliance on 
glycolysis can be further accentuated under the hypoxic conditions that operate within many 
tumours. In fact, the hypoxia response system acts pleiotropically to up-regulate glucose 
transporters and multiple enzymes of the glycolytic pathway. Thus, both the Ras oncoprotein 
and hypoxia can independently increase the levels of the hypoxia-induced factor (HIF), HIF1α 
and HIF2α, which in turn up-regulate glycolysis [Hanahan and Weinberg, 2011]. 
Activating (gain-of-function) mutations in the isocitrate dehydrogenase 1/2 (IDH) 
enzymes genes have been reported in glioma and other human tumours [Hanahan and 
Weinberg, 2011]. Cells with these mutations were possibly clonally selected for their ability to 
alter energy metabolism, as data associates IDH activity with elevated stability of the HIF-1 
transcription factors which in turn affects genome stability and angiogenesis/invasion, blurring 
the lines of phenotypic demarcation [Hanahan and Weinberg, 2011]. As a consequence, the 
designation of reprogrammed energy metabolism as an emerging hallmark seems most 
appropriate to highlight both its evident importance and the unresolved issues surrounding its 
functional independence from the core hallmarks [Hanahan and Weinberg, 2011].  
 
 
1.5. MICROENVIRONMENT AND CANCER 
Cellular microenvironment is, by definition, the cell-surrounding medium, constituted by 
a diversity of molecules secreted by the neighbouring cells and by cells, namely the fibroblasts 
that form the ECM [Bissell et al., 2005; Hu and Polyak, 2008]. Though there is little doubt that 
multiple genetic alterations are necessary for epithelial cells malignant transformation to take 
place, several lines of evidence suggest that the progress towards full malignancy, of cells that 
bear potentially oncogenic mutations, requires a permissive tissue microenvironment [Wright 
and Shay, 2002; Bissell et al., 2005; Parrinello et al., 2005; Hu and Polyak]. 
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As focused earlier, fibroblasts are known to be part of the connective tissue, with 
supportive and feeder function towards the epithelial cell layer. Fibroblasts have the ability to 
secrete various ECM components namely collagen type IV, dystroglycan and EGF, as well as 
metalloproteinases (MMPs) and cytokines, contributing to the homeostasis of the cells 
[Junqueira and Carneiro, 2008; Krtolica and Campisi, 2002; Parrinello et al., 2005]. 
Mutational events and the existence of genetic polymorphisms on fibroblasts can induce gene 
function gain or loss and consequently changes in protein expression [Bissell et al., 2005]. 
For the formation of tumours, there is a great contribution from the stimuli resulting 
from the ECM [Krtolica and Campisi, 2002; Bissell et al., 2003; Ghajar and Bissell, 2008]. It is 
increasingly apparent that crosstalk between cancer cells and cells of the neoplastic stroma is 
involved in the acquired capability for invasive growth and metastasis. Such signalling may 
impinge on carcinoma cells and act to alter their hallmark capabilities. For example, 
mesenchymal stem cells (MSCs) present in the tumour stroma have been found to secrete 
Chemokine (C-C motif) ligand 5 (CCL5), also known as RANTES, in response to signals released 
by cancer cells; CCL5 then acts reciprocally on the cancer cells to stimulate invasive behaviour 
[Hanahan and Weinberg, 2011]. Published results revealed that in epithelial cells, particularly 
in breast tissue, there is an increased cell polarization due to changes in the microenvironment 
induced by fibroblasts [Ghajar and Bissell, 2008]. 
It has been shown that the histological appearance of the epithelial cells can vary 
according to the type of cells that surround them [Olumi et al., 1999]. In a prostate carcinoma 
study, it has been observed that epithelial cells combined with CAFs formed an epithelial 
ductal structure lined with an abnormal stratified squamous epithelium, poorly differentiated. 
In contrast epithelial cells in the presence of normal fibroblasts formed ductal structures lined 
by tall columnar epithelial cells that expressed prostate-specific antigen (Figure 1.9) [Olumi et 
al., 1999]. 
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Figure 1.9: Histological images of tissue recombinants of Carcinoma-Associated Fibroblasts (CAF) in a human 
prostate Epithelium (E); Normal Human Prostate Fibroblasts (NHPF) in a normal in a human prostate Epithelium (F) 
(adapted from Olumi et al., 1999). 
 
Aging can give way to accumulation of genetic mutations and/or unfavourable conditions 
for cells, prone to the stage of senescence [Wright and Shay, 2002]. These changes, both on 
fibroblasts and epithelial cells, render cells vulnerable to changes in the microenvironment [Hu 
and Polyak, 2008]. However, phenotypic changes on epithelium require less mutations than 
on fibroblasts to occur [Krtolica and Campisi, 2002; Parrinello et al., 2005].  
 
 
1.6. SENESCENCE 
Senescence frequently appears as a strategy organisms develop to expand their lifespan 
by inhibiting several death causes, namely in cancer [Campisi, 2005]. However, the fact that 
aging favours the emergence of carcinomas leads to the hypothesis that traits selected to 
maintain early life fitness can have unselected deleterious effects late in life, a phenomenon 
termed antagonistic pleiotropy [Krtolica et al., 2001; Krtolica and Campisi, 2002; Campisi, 
2005].  
Cellular senescence is the ultimate and irreversible loss of replicative capacity and, 
consequently, although growth arrested cells maintain their viability [Krtolica et al., 2001; 
Krtolica and Campisi, 2002; Wright and Shay, 2002; Cooper and Haussman, 2009]. At the 
cellular level cellular senescence is characterized by an arrest in G1 cell-cycle phase, altered 
gene expression, resistance to apoptosis and changes in the cellular differentiation status 
[Goodwin et al., 2000; Krtolica and Campisi, 2002; Wright and Shay, 2002]. Mechanistically, 
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cellular senescence is related to shortening of telomeres, which are repetitive sequences of 
DNA at the chromosomal ends. Telomere functions comprehend the protection of 
chromosomes’ wealthy regions on genetic information, the maintenance of chromosomes 
integrity, avoiding chromosomal fusion and maintenance of DNA replication ability [Lodish et 
al., 2004]. Immediately after cellular differentiation, there is loss of telomerase activity, which 
results in telomere shortening and increased probability of DNA loss at sub-terminal level 
[Krtolica et al., 2001; Krtolica and Campisi, 2002; Wright and Shay, 2002; Campisi, 2005].  
Another type of senescence is the stress-induced senescence and has nothing to do with 
telomeres shortening. This process is triggered in still healthy young cells by external agents 
that induce DNA damage, reactive oxygen species (ROS) or gain of function of oncogenes or 
loss of tumor suppressor genes, [Coppé et al., 2008a; Campisi, 2005]. In the specific case of 
cancer, it can also be triggered by other forms of intracellular deregulation that can affect 
mitosis control [Krtolica et al., 2001; Krtolica and Campisi, 2002; Wright and Shay, 2002; 
Campisi, 2005].  
 
 
 
 
 
 
Figure 1.10: Morphologic images of normal fibroblasts (A) and senescent fibroblasts (B) (adapted from Narita et al., 
2003). 
 
There are different senescence sub-phenotypes depending on the cell type [Krtolica and 
Campisi, 2002; Parrinello et al., 2005]. The senescence-associated phenotypic changes in 
fibroblasts derive from a series of molecular events at cellular level that can be used as 
markers. In fibroblasts, senescence is associated with an increased neutral β-galactosidase 
activity (SA-βgal), although SA-βgal involvement in tumour onset and progression remains 
unknown [Dimri et al., 1995; Krtolica and Campisi, 2002; Parrinello et al., 2005]. Senescent 
fibroblasts are also characterized by the emergence of unique structures on their 
heterochromatin, named as senescent-associated heterochromatic foci [Narita et al., 2003], as 
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well as an increased secretion of factors as EGF [Krtolica and Campisi, 2002; Parrinello et al., 
2005], heregulin [Krtolica and Campisi, 2002; Parrinello et al., 2005] or HGF [Coppé et al., 
2008b]. These changes, capable of triggering proliferative responses on other cell types, are 
TGF-β-dependent, even though TGF-β expression can vary from phenotype to phenotype 
[Bissell et al., 2005; Littlepage et al., 2005; Parrinello et al., 2005; Skibinski et al., 2007; Hu 
and Polyak, 2008]. It has been reported that up to 40 differents factors present increased 
secretion in senescent fibroblasts [Laberge et al., 2011]. Morphologically senescent fibroblasts 
are larger and more planar-like (Figura 1.10) [Krtolica and Campisi, 2002]. 
Figure 1.11: Soluble factors secreted by different strains of fibroblasts, both senescent and presenescent (adapted 
from Coppé et al., 2008b). 
 
Figure 1.12: Senescent fibroblast (blue nucleus) in the stroma secretes various factors that stimulate pre-neoplastic 
epithelial cells (yellow cells) to proliferate (A). Further, the SASP stimulates transformed cells to undergo an EMT 
(orange cells). (B) Finally, the SASP promotes the invasion of mesenchymal-like cells (red cells) through the 
surrounding stroma (C) (adapted from Laberge et al., 2011). 
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Recently, senescent fibroblasts were demonstrated to induce proliferation of epithelial 
cells with pre-malignant and malignant mutations without, however, affecting the proliferation 
of normal cells [Krtolica et al., 2001]. The increase on cells’ proliferation was achieved either 
by direct contact with senescent fibroblasts or indirectly by factors secreted by fibroblasts 
[Krtolica et al., 2001; Krtolica and Campisi, 2002; Coppé et al., 2008a; Hu and Polyak, 2008]. 
In mice, senescent fibroblasts, much more than pre-senescent fibroblasts were reported to 
induce pre-malignant and malignant epithelial cells to form tumours [Krtolica and Campisi, 
2002]. This result evidenced what is considered evolutionary antagonistic pleiotropy because 
cellular senescence suppresses tumourigenesis early in life and promotes cancer in aged 
organisms [Krtolica et al., 2001].  
Senescent fibroblasts secret certain metalloproteinases [Krtolica and Campisi, 2002; 
Bissell et al., 2005; Parrinello et al., 2005), as collagenase I (MMP1), collagenase III (MMP3) 
[Krtolica and Campisi, 2002; Parrinello et al., 2005] and stromelysin-1 [Krtolica and Campisi, 
2002], and interleukins (IL) [Krtolica and Campisi, 2002; Bissell et al., 2005; Parrinello et al., 
2005; Coppé et al., 2008b], as well as increased amounts of fibronectin [Krtolica and Campisi, 
2002]. The expression of metalloproteinases, is directly accountable for collagen stability and 
degradation [Bissell et al., 2003; Bissell et al., 2005; Ghajar and Bissell, 2008], and consequent 
structural disorganization of the ECM, which will induce loss of epithelial cells stability [Bissell 
et al., 2005] and changes in the differentiation pattern in order to survive [Bello-DeOcampo et 
al., 2001; Bissell et al., 2005]. Increased levels of metalloproteinases and ILs were also 
reported to induce increased levels of ROS in epithelial cells that, in turn, will induce changes 
on oxidative metabolism [Bissell et al., 2005]. Under this microenvironment, as fibroblast and 
epithelial cells co-evolved, the malignization of one of these cell types becomes a probable 
event, possibly as the result of certain oncogenes expression [Krtolica and Campisi, 2002]. 
Under appropriated conditions, newly transformed cells can stimulate, through paracrine 
mechanisms, another cell type proliferation. The latter, in turn, will express growth factors that 
will affect the former cells, giving way to an ascendant stimuli-response-stimuli cascade, 
increasing exponentially the proliferation of the tumoral mass [Bissell et al., 2005; Campisi, 
2005].  
From the various genes that induce phenotypic changes it should be emphasized that, as 
they are involved in checkpoints, tumour-suppressor genes don’t allow the proliferation of 
potentially neoplastic cells [Campisi, 2005]. Thus, the senescent phenomenon is, in part, 
similar to apoptosis, with the big difference that apoptosis results in cells’ death while 
senescence only prevents cells’ replication [Krtolica et al., 2001]. In this process the 
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microenvironment has a controller and determinative role, deciding between survival or death 
pathways, therefore being able to seal the cell’s fate. 
Figure 1.13: Representation of hallmarks of senescent cells. Senescent cells differ from other nondividing 
(quiescent, terminally differentiated) although, no single feature of the senescent phenotype is exclusively specific. 
Hallmarks of senescent cells include an essentially irreversible growth arrest, expression of SA-βgal and p16
INK4a
, 
robust secretion of numerous growth factors, cytokines, proteases, and other proteins, and nuclear foci containing 
DNA damage response proteins (DNA-SCARS/TIF) or heterochromatin (Senescent Associated Heterochromatin Foci 
(SAHF). The pink circles in the nonsenescent cell (left) and senescent cell (right) represent the nucleus (adapted 
from Rodier and Campisi, 2011). 
Figure 1.14: The senescent phenotype induced by multiple stimuli. Mitotically competent cells respond to various 
stressors by undergoing cellular senescence. These stressors include dysfunctional telomeres, non-telomeric DNA 
damage, excessive mitogenic signals including those produced by oncogenes (which also cause DNA damage), non-
genotoxic stress such as perturbations to chromatin organization and, probably, stresses with an as-yet-unknown 
etiology. The senescence response causes striking changes in cellular phenotype. These changes include an 
essentially permanent arrest of cell proliferation, development of resistance to apoptosis (in some cells), and an 
altered pattern of gene expression (adapted from Campisi and d'Adda di Fagagna, 2007). 
 
 
1.6.1. MOLECULAR MECHANISMS OF SENESCENCE 
P53 pathway is activated in response to the DNA damage that results from extremely 
short or dysfunctional telomeres or from the excessive production of ROS [Campisi, 2005; 
Feng et al., 2007; Rodier et al., 2007]. As a consequence, p21 is activated by p53 and changes 
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in gene transcription are triggered. The ultimate result can be cellular senescence [Campisi, 
2005; Rodier et al., 2007; Lisanti et al., 2010].  In fact, the senescent response is dependent 
upon p53 and pRb-associated pathways, even though the major mechanistic features 
underlying the process are still unknown [Krtolica and Campisi, 2002; Campisi, 2005]. With 
aging, the loss of heterochromatin allows certain genes, previously silenced, to be expressed 
by activation through pRb/E2F pathway, potentiating cell proliferation and consequently 
tumour formation [Campisi, 2005]. In addition, loss of p53 activity induces uncontrolled 
proliferation due to loss of cell-cycle control, allowing previously senescent cells to no longer 
be such [Bissell et al., 2005; Campisi, 2005].  
Regarding pRb pathway, the activation of RAS signal transduction pathway, due to 
intracellular stress and oncogenes, induces the activation of p16, inhibiting the cell-cycle 
which, in turn, will activate pRb. The chromatin reorganization, due to the activation of pRb 
affects E2F-dependent-gene transcription, as well as other genes associated with proliferation 
[Goodwin et al., 2000; Campisi, 2005]. 
Finally, p53 and pRb pathways are inter-connected by the fact that active p53 leads to 
p21 activation, and consequent inhibition of cyclin-dependent-kinases (CDK4, CDK6) thus, 
promoting pRb hyperphosphorylation and subsequent activation, resulting in the emergence 
of an apparently irreversible senescence state [Campisi, 2005]. Even inactivating p53, 
supposedly reversing the senescent state, the pRb activation via p53-independent pathways 
would not reverse the senescent phenotype [Campisi, 2005; Coppé et al., 2008b]. Due to the 
fact that few cells are capable of expressing both p21 and p16, the predicted simultaneous 
activation cascade of p53 and pRb pathways is not viable in most tissues [Campisi, 2005]. On 
the other hand, the silencing or reduction of p16 expression, by the respective promoter 
hypermethylation, inhibiting the pRb pathway leads to senescent response through p53 
pathway [Campisi, 2005; Rodier et al., 2007]. However, posterior inhibition of p16, p53 or 
even pRb proteins does not reverse the senescent stage [Goodwin et al., 2000; Campisi, 
2005]. 
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Figure 1.15: Representation of the senescence effector pathways crosstalk through p53 and pRb (adapted from 
Vergel et al., 2010). 
 
 
1.7. CHROMIUM, HEXAVALENT CHROMIUM AND CANCER 
Chromium is a ubiquitous metal in nature, being present in soil, rocks and living 
organisms. The metal was discovered at the end of the XVII century by Nicolas-Louis Vauquelin 
on a plumb mineral, croicote (PbCrO4). It is a transition element, located at group IV of the 
periodic table, being a mixture of 4 stable isotopes: 50Cr (4.31%), 52Cr (83.76%), 53Cr (9.55%) 
and 54Cr (2.38%) [Cotton and Wilkinson, 1998]. This transition metal with incomplete d 
orbitals can present various oxidative states from 2- to 6+ (VI) being the 3
+ (III) the more stable 
[Salnikow and Zhitkovich, 2008]. Chromium is widely used in textile, metallurgic and in 
stainless and chromed steel industries. Cr(II) oxidation state is a strong reducing agent and 
when exposed to air or water can, rapidly, generate the more stable trivalent state. 
Biologically, Cr(III) potentiates insulin activity, being indirectly involved on the glucose uptake. 
*O’Brien et al., 2003; Barceloux, 1999].  Chemically, Cr(III) compounds are less soluble in water 
at a 4-11 pH, while in alkaline environment can be easily oxidized to the hexavalent form 
[Barceloux, 1999]. Cr(VI), obtained in nature from fossil combustion, can be found on Earth in 
the form of chromate (CrO4
2-) or dichromate (Cr2O7
2-) salts, recognized respectively by yellow 
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and orange colours. It is biologically a very toxic agent mostly because its great reduction 
potential makes it a strong oxidative agent. It is easily inhaled, entering the organisms’ 
respiratory tract and it is also quite soluble, being easily absorbed to the blood stream 
[Barceloux, 1999]. 
Cr(VI) compounds are largely used in the production of stainless steel, textile dyes, wood 
preservation, leather tanning, anti-corrosive and conversion coatings. As a consequence, 
chromium industrial wastes released into the environment easily contaminate pristine waters 
and the atmosphere. Although Cr(III), in the form of chromium oxide, is the more abundant 
environmental contaminant, Cr(VI) can also appear in burned coal ashes [Stern, Thomsen and 
Furst, 1984]. However, the slow oxidation of Cr(III) to Cr(VI) renders accumulation of industrial 
wastes a huge health problem.  
Cr(VI) compounds (chromates) can easily cross the biologic membranes, through anionic 
unspecific channels, as chromate salts have a tetrahedral geometry portraying structural 
similarities to sulphate and phosphate salts. Chromate salts carcinogenicity was revealed 
following epidemiologic studies on exposed miners and refinery workers [Manahan, 2003; 
Barceloux, 1999; Salnikow and Zhitkovich, 2008]. Exposure to environments contaminated 
with chromate can cause bronchogenic carcinoma, as the respiratory tract tissues are in direct 
contact with inhaled Cr(VI), with a latent period from 10 to 15 years [Manahan, 2003; 
Barceloux, 1999]. The International Agency of Research on Cancer (IARC) considers Cr(VI) as a 
group 1 carcinogenic lung agent [Urbano et al., 2008].  
The carcinogenicity of Cr(VI) compounds has been explained by its easy intracellular 
accumulation and reduction to Cr(III) by glutathione, cysteine and ascorbate. During the 
reduction process, the very reactive Cr(V) and Cr(IV) intermediates can easily generate a 
variety of extremely reactive carbon, oxygen and sulphur centred  radicals leading directly or 
indirectly to DNA and proteins damage [Urbano et al., 2008; Reynolds et al., 2007]. Cr(III) also 
reacts with DNA, generating binary and ternary Cr-DNA adducts, protein-Cr-DNA cross-links 
and bi-functional DNA-Cr-DNA inter-strand cross-links [Zhitkovich, 2005]. The ultimate result 
of Cr(VI) reduction process is DNA- single and - double strand breaks formation and a 
consequent activation of DNA repair systems which,  when mutated or to slow to repair the 
extensive damage, may lead to chromosomic instability and cellular dysfunction [Urbano et 
al., 2008] (Figure 1.16).  
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Figure 1.16: Schematic representation of possible pathways involved on Cr(VI)-induced carcinogenesis (adapted 
from Urbano et al., 2008). 
 
Exposure to Cr(VI) was reported to induce senescence, anchorage independence and 
mutations on human foreskin fibroblasts [Biedermann and Landolph, 1987]. The exposure 
regimen used in this study suggests that Cr(VI) may contribute to the development of cancer 
through its mutagenic effects, but also by ROS-mediated changes in stromal fibroblasts 
secretory phenotype. In fact, senescence is known to emerge in response to DNA damage and 
ROS formation [Campisi, 2005; Rodier et al., 2007; Lisanti et al., 2010]. 
A major drawback for the acceptance of most of the data obtained from in vitro studies 
relies on the fact that studies, that detected some of these mutagens and their DNA injuries, 
do not represent the in vivo events. The cell types used in most studies  were not respiratory 
tract cells, the exposure regimens used were not representative of the carcinogenic process, 
and the results obtained were heavily dependent upon the system and experimental 
conditions employed [Urbano et al., 2008; Rodrigues et al., 2009]. However, very recently, it 
was successfully induced the malignant transformation of an SV40 immortalized human 
bronchial epithelial cells (BEAS-2B) following prolonged exposure to sub-cytotoxic Cr(VI) 
concentration [Rodrigues et al., 2009].  
To better depict the in vivo events occurring in Cr(VI) lung carcinogenesis a cellular model 
in which epithelial cells co-evolved together with bronchial fibroblasts will have to be 
established since, it is well documented that homeostasis of epithelial organs such as lung 
critically depends on interaction with the adjacent mesenchyme [Andriani et al., 2003; Coppé 
et al., 2008a; Hu and Polyak, 2008; Hyatt et al., 2004; del Moral et al., 2006]. But, the study of 
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the molecular mechanisms of these interactions in vivo is complicated by many variables and 
the lack of properly controlled experimental conditions. Epithelial–mesenchymal synergy has 
been frequently approached by using three-dimensional organotypic co-cultures of epithelial 
cells and fibroblasts embedded in different matrices. These complex culture models have 
provided valuable information on ultrastructural features of epithelial cells’ differentiation and 
basement membrane formation [Andriani et al., 2003] but are not amenable for detailed 
biochemical studies.  
 
 
1.8. CELL CULTURE 
Cell culture is a technique used in diverse fields of research. Its focus is the study of 
biological events in controlled conditions. Nowadays, cell culture importance is easily 
recognized as it allows a continuous analysis of multiple biological processes and properties in 
tissue cells that otherwise would be impossible to analyze in living organisms. Using such 
technique it has been possible to identify the genetic bases and phenotypic processes involved 
in cellular transformation and to compare, among other pathologies, normal and tumour cells’ 
behaviour [Freshney, 2005; BéruBé et al., 2010]. 
Cell culture was devised as a method to study the behaviour of animal cells, with the 
interference from systemic variable that frequently appear in vivo [Freshney, 2005]. As such, 
this in vitro technique, allows the controlled introduction of variables in the sample 
environment, increasing phenotype homogeneity proportional with passage number and 
observing their effects in the cells. Growth factors, nutrients needed and dosages, as well as 
pH and the presence of inorganic salts, CO2 concentration and temperature, among others are 
major factors for the appropriate cell development. Therefore, it’s very important to have an 
appropriate cell medium for each cell culture [Freshney, 2005]. The use of cell lines is 
extremely useful, as there is the production of an acceptable number of same type of cell, 
being able to be crio-preserved. Unfortunately, they can lose a great deal of the original tissue 
phenotype [Sigma Cell Culture Manual Data Sheet, 2005].  
Cell culture can be performed with cells in cellular suspensions or adherent plain surfaces 
forming monolayers [Freshney, 2002]. In suspension, cells grow in solution, forming small 
individualized aggregates, while in monolayers cells grow attached to the surface of the culture 
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flask. The culture type reflects the cells’ origin, being that fluid tissue cells grow better in 
suspension, while solid tissue cells grow better in monolayer. It the latter case is easy to 
classify cells according to their morphology as endothelial, epithelial, neuronal or fibroblasts, 
among others [Sigma Cell Culture Manual Data Sheet, 2005; Freshney, 2002]. 
 
Figure 1.17: Evolution of a Cell Line. The vertical (Y) axis represents total cell growth (assuming no reduction at 
passage) for a hypothetical cell culture. Total cell number (cell yield) is represented on this axis on a log scale, and 
the time in culture is shown on the X-axis on a linear scale. Although a continuous cell line is depicted as arising at 
14 weeks, with different cells it could arise at any time. Likewise, senescence may occur at any time, but for human 
diploid fibroblasts it is most likely to occur between 30 and 60 cell doublings, or 10 to 20 weeks, depending on the 
doubling time (adapted from Freshney, 2005). 
 
 
1.8.1. PRIMARY CELL CULTURES 
Cell cultures can be classified as primary and continuous cultures [Freshney, 2005]. 
Primary cultures are obtained directly from tissues, normally through biopsies. They are 
initially heterogeneous, and reflect the characteristics they had in vivo. However, its 
preparation and maintenance is exhaustive and cultures can only be kept in vitro for short 
periods of time [Sigma Cell Culture Manual Data Sheet, 2005]. This is due to the fact that, 
with aging, all tissues lose their ability to proliferate correctly. Depending on cell type the loss 
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of ability can vary. The turning point in time, in which cells stop normally proliferating and can 
go either through senescence or undergo transformation (possibly malignant), is called 
Hayflick Limit. This point is related to telomere shortening that occurs with aging, which can 
activate cell cycle arrest and therefore normal growth [Freshney, 2005] 
Once in culture, primary cell lines grow to the confluence, stage at which they stop 
growing in a process called contact inhibition growth. If this primary culture is subjected to 
chemical or mechanical disaggregation and cells are re-plated in a lower density, a process 
called sub-culture of passage, a primary cell line is attained [Freshney, 2005]. Continuous cell 
culture, derive from primary cultures by a process of sub-culture or passage. These cultures 
are usually called cell lines. The cells’ variety in each cell tends to diminish along time and 
cultures can be propagated for a finite number of cell division, normally about 30. Finite cell 
lines are generally diploid and present a certain degree of differentiation. In these cell lines it 
should be considered the emergence of senescent phenotype on latter passages, in order to 
maintain a proper culture [Freshney, 2005; Sigma Cell Culture Manual Data Sheet, 2005].  
 
 
1.8.2. BEAS-2B CELL LINE 
BEAS-2B cell line is a commercialized and transformed bronchial epithelial cell line. The 
cell line was initially isolated from normal human bronchial epithelium, obtained from autopsy 
of non-cancerous individuals. The cells were immortalized through infection with an 
adenovirus 12-SV40 virus hybrid. They are normally used in screening from chemical and 
biological agents for their ability to induce and affect differentiation or carcinogenic 
development. 
This cell line was produced in 1988 at the National Cancer Institute, USA, by a group lead 
by Curtis Harris. [Reddel et al., 1988] It is capable to be maintained up to a year in culture, a 
big advantage compared to primary cultures. Although not tumorigenic it can suffer genomic 
alterations that can induce a change in phenotype. Recently, it has been shown that Cr(VI) 
exposure can induce malignant transformation. [Rodrigues et al., 2009; Costa et al., 2010] 
Therefore, in alternative to the HBEC primary cultures due to difficulty in establishment a 
stable and long-term culture, BEAS-2B present themselves, due to their already known 
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characterization and increased stability in culture, as the best way to study the effect of 
senescent fibroblasts on bronchial epithelial cells. 
 
 
1.8.3. CO-CULTURES  
As mentioned earlier, EMT and subsequent mesenchymal-epithelial (MET) transitions 
associated with alterations in E-Cadherin expression and are among the most dramatic 
examples of cells’ plasticity in response to their microenvironment. In addition, they represent 
critical steps in tumour progression. Among the crucial signals that govern cell behaviour are 
those generated locally by neighbouring cells. Understanding how fibroblasts and epithelial 
cells interact with and modulate their microenvironment can provide insights into the 
molecular mechanism(s) involved with malignant transformation. To study these signalling 
mechanisms in a controlled setting, several co-culture systems have been developed. 
Co-cultures have been especially useful in understanding the interactions between 
epithelial cells and stromal fibroblasts during normal development and neoplastic 
transformation, having shown that stromal fibroblasts are essential regulators of normal 
epithelial cell phenotypes and the malignant phenotypes of pre-neoplastic or neoplastic 
epithelial cells [Martinez-Outschoorn et al., 2010]. 
 
 
1.8.3.1. CO-CULTURE OF LUNG FIBROBLASTS AND BRONCHIAL EPITHELIAL 
CELLS  
Normal human bronchial epithelial (NHBE) cells have the ability to strongly develop a 
mucocilliated morphology in air-liquid interface, similar to what is observed in vivo 
[Wiszniewski, Jornot, Dudez et al., 2006]. However, NHBE primary cultures have a very short 
lifespan and can contain different cell types. Although, minor cell populations can be removed 
through cell passage, primary cultures are rather prone to phenotypic changes, and the 
proliferation rate is very small due to the lack of the ECM supporting layer which, in addition to 
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fibroblasts, contains other factors e.g., growth factors and hormones, needed for phenotype 
maintenance [Freshney, 2002]. The mutual regulation between the matrix and the epithelium 
is required for phenotype maintenance and normal development, playing also a crucial role in 
cellular (de)differentiation and transformation [Freshney, 2002; Wiszniewski, Jornot, Dudez et 
al., 2006; Pohl et al., 2009).  
Immortalized or tumorigenic fibroblast cell lines rather than normal fibroblasts have been 
used to study fibroblast/epithelial interactions during tumour growth and development. These 
studies revealed that fibroblast cell lines that have been altered by viral or chemical 
carcinogens can enhance tumor growth when co-inoculated with carcinoma cells [Olumi et al., 
1999].  
Recently, Chanson’s group [Wiszniewski et al., 2006], using transwells, successfully 
implemented a bronchial epithelial cell culture method, that keeps cells without any 
phenotypic change for extended periods of time (as long as 6 months) [Wiszniewski et al., 
2006; Pohl et al., 2009]. In Chanson’s co-cultures method, fibroblasts were seeded on a 
bottom layer of a multiwell, without being in direct contact with the epithelial layer present in 
the transwell compartment (Figure 1.17). Nevertheless, although the fibroblasts were not in 
direct contact with the epithelial cells, their secretion products (chemokines and cytokines) 
were able to reach the epithelial compartment through the porous membrane, mimicking the 
supportive and reciprocal connection between both cell layers. As the porous membrane 
separates the two compartments, it was impossible the contact between different cell layers, 
avoiding any possible cell invasion. Additionally, the porous membrane also allowed the use of 
different cell type specific medium [Wiszniewski, Jornot, Dudez et al., 2006; Pohl et al., 2009].   
Figure 1.18: Co-culture in vitro system with NHBE and fibroblasts (adapted from Pohl et al., 2009). Fibroblasts are 
cultured on the bottom compartiment, with the culture medium in direct contact with a filter membrane with 0.4 
µM pores, on the base of transwell, allowing growth factors and other molecules to pass to the upper 
compartiment, being in contact with NHBE cells, leading to a condition resembling the in vivo situation where NHBE 
proliferation and differentiation is modulated by the ECM. 
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Using a similar methodology Chanson demonstrated that the epithelial phenotype 
depends on the origin of fibroblasts feeder layer. Therefore, co-cultivating nasal polyps’ 
epithelial cells in the presence of a feeder layer of bronchial fibroblasts it was possible to 
obtain ciliated epithelia, following epithelial proliferation and subsequent removal of the 
epithelial cell culture medium (Figure 1.18) [Wiszniewski et al., 2006].  
Figure 1.19: Representation of the proliferation and differentiation process in co-culture of NHBE and fibroblasts 
(adapted from Wisniewski, Jornot, Dudez et al., 2006). 
  
 
1.9. OBJECTIVE 
Most studies on the mechanisms leading to cells’ malignant transformation that use 
epithelial cell monocultures assumed that tumour microenvironment was a passive and inert 
entity. However, the behaviour of epithelial cells is easily modulated by extracellular 
microenvironment and culture conditions. Consequently, it is not surprising that gene 
expression changes observed in cancer cells from epithelial cell monocultures, often cannot be 
validated in clinical specimens and the screening of drugs for cancer treatment has rarely 
resulted in the identification of a clinically successful chemotherapeutic agent.  
Understanding how epithelial cells and fibroblasts interact with and modulate their 
microenvironment can provide insights into the molecular mechanism(s) involved with 
malignant transformation and progression. Aiming to implement an in vitro model of Cr(VI)-
induced carcinogenesis that better depicts what is observed in vivo, co-cultures of Cr(VI)-
induced senescent fibroblasts and Cr(VI)-exposed human epithelial cells will be established. 
Through the implementation of this model it is expected to shed some light on the role of 
cellular senescence on the malignant transformation of human bronchial epithelium. 
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In the course of this project several techniques were used ranging from basic 
biochemical laboratory procedures and cell culture, to molecular techniques as immunological 
staining. In this section all the experimental protocols used in this work will be presented, as 
will all the materials and equipment used, and their respective manufacturers. 
 
 
2.1. REAGENTS AND MATERIAL 
Whenever necessary, ultrapure water obtained from a SimplicityTM (Millipore S.A., 
Molsheim) water purification system was used.  
 
Reagents purchased to Sigma-Aldrich Química S.A., Sintra, Portugal: 
 Different salts for Phosphate Buffer Solution (PBS) preparation, namely KCl, NaCl, 
KH2PO4 and Na2HPO4; 
 NaOH used for the preparation of the pH adjustment solution; 
 Trypan Blue 0,4% solution (m/v) in PBS, used in cell counting; 
 Potassium dichromate used for preparation of hexavalent chromium [Cr(VI)] solutions; 
 Dimethyl sulphoxide (DMSO) used for cell culture cryopreservation; 
 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) powder used for 
cell viability assays; 
 Senescent cells staining kit used in the senescence evaluation assays; 
 2 % gelatine from bovine skin used to prepare the coating solution; 
 Ammonia hydroxide used in the preparation of the type I collagen coating solution; 
 Bovine serum albumin for the preparion of the 1 % gelatine solution. 
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Reagents purchased to Gibco, CA, USA, through Alfagene, Lisbon, Portugal: 
 TrypLE Express 0,25 % trypsin solution to detach cells; 
 Transferrin, sodium pyruvate and L-glutamine, used as medium supplement for 
bronchial epithelial primary cells cultures; 
 Foetal bovine serum (FBS), used in fibroblasts primary cell culture; 
 Dulbecco’s Modified Eagle Medium (DMEM) and F12 cell culture mediums, used in 
fibroblasts primary cell cultures; 
 LHC-9 cell culture medium, used for epithelial cell cultures 
 Type I collagen, used in the preparation of a coating solution for primary bronchial 
epithelial cells; 
 Penicillin and streptomycin used in the preparation of some cell culture mediums. 
 
Reagents purchased to Invitrogen, CA, USA, through Alfagene, Lisbon, Portugal: 
 Epidermal growth factor, used as a medium supplement for primary bronchial 
epithelial cells cultures. 
 
Reagents purchased to Panreac Química S.A., Barcelona, Spain: 
 Absolute ethanol used for cell fixation protocol during the immunocytochemistry 
analysis. 
 
Reagents purchased to Merck, Darmstadt, Germany, through VWR International, Lisbon, 
Portugal: 
 Hydrochloric acid and isopropanol, used in the MTT assay; 
 Acetic acid, used for type I collagen coating solution preparation. 
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Reagents purchased to Lonza, MD, EUA, through VWR International, Lisbon, Portugal: 
 Bronchial Epithelial Growth Medium (BEGM) used for bronchial epithelial primary cells 
culture. 
 
Reagents purchased to Roche, Sistemas de Diagnosticos Lda., Amadora, Portugal: 
 Pronase utilized during the establishment of primary bronchial epithelial cultures. 
 
From European Collection of Cell Cultures (ECACC), were purchased: 
 BEAS-2B cell line as a cryopreserved cellular suspension, used in the co-cultures. 
 
From Orange Scientific, Braine-l’Alleud, Belgium, through Frilabo, Porto, Portugal: 
 96-wells tissue culture test plates, used for the MTT assay; 
 15 and 50 mL centrifuge tubes. 
 
From Corning Incorporated, NY, EUA, through Sigma-Aldrich Química S.A., Sintra, Portugal: 
 12-wells tissue culture test plates, used for cell culture; 
 T25 and T75 tissue culture flasks with vent cap, used for cell culture 
 6-well tissue culture transwells (3450), used in the co-cultures 
 
Reagents purchased to Lab Vision Corporation, Fremont, CA, USA,  
 UltraVision Large Volume Detection System Anti-Polyvalent, HRP (Ready-To-Use) Kit, 
for cell immunocytochemistry analysis. 
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Reagents purchased to Novocastra DakoCytomation, Glostrup, Denmark,  
 Monoclonal mouse anti-human cytokeratin antibody, clone MNF116, used for cell 
immunocytochemistry analysis; 
 Monoclonal mouse anti-human vimentin, clone Vim 3B4, used for cell 
immunocytochemistry analysis; 
 Monoclonal mouse anti-human smooth muscle actin, clone 1A4, used for cell 
immunocytochemistry analysis. 
 
Reagents purchased to Novocastra Laboratories Ltd, Newcastle, United Kingdom,  
 Monoclonal mouse anti-human E-Cadherin antibody, clone 36B5 and 3,3-
diaminobenzidine tetrahydrochloride (DAB), both used during the 
immunocytochemistry procedure. 
 
Reagents purchased to Hanna Instruments, Woonsocket, USA, through Hanna Instruments 
Portugal, Póvoa do Varzim, Portugal: 
 pH meter calibration solutions.  
 
 
Material purchased to Sarstedt Lda., Rio Mouro, Portugal: 
 6 and 24-well tissue culture plates, used for cell culture; 
 25 mL serological pipettes; 
 Petri dishes used for cell culture; 
 Cryogenic vials utilized in cells’ cryopreservation; 
 2 mL microcentrifuge tubes. 
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Material purchased to Frilabo, Porto, Portugal: 
 2, 5, 10 mL serological pipettes. 
 
Material purchased to Menzel-Gläser, Braunschweig, Germany, through VWR International, 
Lisbon, Portugal: 
 Coverslips and slides, used for immunocytochemistry analysis. 
 
Material purchased to Schleicher & Shuell, Microscience, Dassel, Germany, through 
Reagente 5, Porto, Portugal: 
 0.2 µm filters, model FP30 utilized in the sterilization of small volume solutions. 
 
 
2.2. EQUIPMENT AND SOFTWARE 
 Bench autoclave, model Omega Media from Prestige Medical, Blackburn, UK, 
distributed by Ezequiel Panão Jorge, Electromédica, Coimbra, Portugal; 
 Water purification system, model SimplicityTM from Millipore S.A., Molsheim, France, 
distributed by Interface, Equipamento e Técnica Lda, Amadora, Portugal; 
 Automatic pipetting aid, model ComfoPette from Orange Scientific, Braine-l’Alleud, 
Belgium, distributed by Frilabo, Porto, Portugal; 
 Haemocytometer from Marienfeld, Germany, distributed by Reagente 5, Porto, 
Portugal; 
 Laboratory hotte from Ibérica Industrial Laborum, distibuited by the same company; 
 Heating plate with magnetic stirrer, model Monotherm from Variomag, Daytona 
Beach, Florida, USA; 
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 pH meter, model HI 110 from Hanna Instruments, Woonsocket, USA, distributed by 
Hanna Instruments Portugal, Póvoa do Varzim, Portugal; 
 Precision weight balance, model Sartorius B P210 S from Sartorius AG, Goettingen, 
Germany, distributed by Sartorius Lda, Lisbon, Portugal; 
 Centrifuge model Heraeus Instruments, Labofuge 400e from Thermo Scientific, 
Waltham, Massachussets, USA, distributed by SupplyLab, Cacém; 
 Flux cabinet model VBH Compact Cabinet from Steril Manufacturing Division, Milan, 
Italy; 
 Inverted microscope, model Nikon Eclipse TS100 from Nikon, USA, distributed by 
Nikon Portugal, Lisbon, Portugal; 
 CO2 Incubator, model CB150 from Binder-World, New York, USA; 
 96-well multiplate reader spectrophotometer, model SLT Spectra, from Alliance 
Analytical Inc.; 
 Liquid nitrogen storage containers model Forma Cryoplus I from Thermo Scientific, 
Waltham, Massachussets, USA; 
 Ultra-low freezer, model -86C ULT Freezer from Thermo Scientific, Waltham, 
Massachussets, USA; 
 Graphpad QuickCalcs and Graphpad Prism 5, from Graphpad Software, La Jolla, 
California, USA, available free online at the website 
http://www.graphpad.com/quickcalcs/index.cfm; 
 Nikon ACT-1 Software, from Nikon, USA, distributed by Nikon Portugal, Lisbon, 
Portugal; 
 Microscope Photographic Camera, model Nikon Digital Camera DXM 1200F, attached 
to inverted microscope Nikon Eclipse 80i, both from Nikon, USA, distributed by Nikon 
Portugal, Lisbon, Portugal 
 Digital photographic camera, model T-100, from Olympus, USA, distributed by 
Olympus Portugal, Lisbon, Portugal 
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2.3. SOLUTIONS AND NUTRIENT MEDIUM PREPARATION 
 Dulbecco’s Modified Eagle Medium (DMEM) : F12 medium (1:1) preparation: 
 To prepare 500 mL of DMEM:F12 (1:1) growth medium, 222.5 mL of DMEM should be 
mix with the same volume of the F12 nutrient mixture. 50 mL of FBS are then added to the 
mixture in order to attain 10 % of the total volume. Finally, 5 mL (1 % of the total volume) of a 
penicillin and streptomycin mixture, containing penicillin at 100 U/mL activity and 
streptomycin at 100 µg/mL concentration, was added to avoid microbial contaminations. 
 
 Phosphate buffer solution 10x concentrated (10x PBS) preparation: 
The 10x PBS stock solution contained 2.68 mM of KCl, 4.15 mM of KH2PO4, 145 mM of 
NaCl and 8,1 mM of Na2PO4 dissolved in ultrapure water. The pH of the solution was adjusted 
to 7.4. 
The 1x PBS solution was obtained by diluting the 10x PBS stock solution with ultrapure 
water. This solution was sterilized prior to use using an autoclave. 
 
 Bronchial Epithelial Growth Medium (BEGM) Preparation:  
This growth medium, commercialized by Lonza, is available in the form of BulletKit®, 
made of Bronchial Epithelial Cell Basal Medium (BEBM) and 9 aliquots of medium 
supplements, that when added to the basal medium, guaranteed optimum growth conditions 
for epithelial cells. The supplements are: epinephrine, retinoic acid, thiiodothrionine (T3), 
hydrocortisone, transferring, a mixture of gentamicin sulphate and amphotericin-B (GA-1000), 
human recombinant epidermal growth factor (rhEGF), human recombinant insulin and bovine 
pituitary extract (BPE). The preparation of the final bronchial epithelial growth medium 
(BEGM) only requires the unfreezing of the aliquots and their addition to the BEBM. 
 
 
46 
 
 
 2 % (w/v)  Bovine serum albumin (BSA) solution preparation: 
The 2 % BSA solution was obtained by dissolving 2 g of BSA on 100 mL of ultrapure 
water. The solution was then homogenized using a magnetic stirrer and subsequently sterilized 
by filtration. 
 
 1 % Gelatine solution preparation: 
To prepare 50 mL of 1 % gelatine solution from the commercial 2% gelatine solution, 
50 mL of the commercial solution were efficiently mixed with 45 mL of 1x PBS and 5 mL of a 
2% BSA solution. 
 
 Collagen type I solution preparation: 
The type I collagen solution was prepared from the commercial type I collagen 
solution. To this end, an initial volume of 25 µL of acetic acid was successively diluted in 
ultrapure water, in a total volume of 25 mL.  287 µL of this acetic acid diluted solution were 
diluted in a total volume of 50 mL. 800 µL this solution were added to a 200 µL solution of 
commercialized type I collagen solution. This solution was then added to 20 mL of 1x PBS and 
preserved at 4 oC. 
 
 Laminin 50 µg/mL solution preparation: 
From a 200 µg/mL laminin stock solution, stored in the freezer for conservation 
purposes, a 50 µg/mL solution was prepared by diluting 1:3 (laminin solution:water) in 
ultrapure water. 
 
 Fibronectin 5 µg/mL solution preparation: 
From a 100 µg/mL fibronectin stock solution, a 5 µg/mL was prepared by dilution in 
ultrapure water, in a ratio of 1:19 (fibronectin solution:water). 
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 500 µM hexavalent chromium [Cr(VI)] stock solution preparation: 
A 500 µM Cr(VI) solution was prepared by dissolving 0.0037 g of potassium dichromate 
(K2Cr2O7) in 50 mL of ultrapure water. 
 
 5 µM hexavalent chromium solution preparation: 
A 5 µM Cr(VI) solution was prepared by dilution of the previously prepared 500 µM 
Cr(VI) solution in a 1:100 ratio with ultrapure water. 
 
 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 0.5 mg/mL 
solution preparation: 
The MTT 0.5 mg/mL solution was prepared by dissolving 75 mg of MTT in 10% 10x PBS 
(15 mL) and 90% ultrapure water (135 mL) under magnetic agitation. The volume was then 
divided in 15 mL aliquots and the aliquots frozen. 
 
 Acid isopropanol crystal dissolving solution preparation: 
In the MTT assay, for absorbance reading, the solution used for crystal dissolution was 
prepared adding 0.5 mL of 37% HCl to 49.5 mL of isopropanol, attaining this way an 
isopropanol solution in 0.1 M HCl. 
 
 
2.4. METHODS 
 Statistical analysis 
Statistical analysis was performed using an unpaired t-test through the GraphPad 
Prism program (GraphPad Software, San Diego, CA). 
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 Digital images 
Throughout this study, cells’ morphology and growth pattern were continuously 
monitored by microscopic observation. Photography’s were obtained using an Olympus T-100 
digital camera. 
 
 
2.4.1. CELL CULTURE 
For the purpose of this work, both bronchial epithelial cells and bronchial fibroblasts 
were cultured using the appropriated cell medium. All cell cultures were implemented in 
aseptic conditions, preventing contamination with microorganisms, and the cells were 
incubated, unless noted, at 37°C in an atmosphere with 5% CO2. 
 Conditions and asepsis 
To ensure asepsis conditions, cell culture was done in a culture room with proper 
ventilation, constant temperature and no direct contact with the outside, as well as presence 
of UV lighting. The flux chamber used was of safety level 2 and was exposed to UV radiation, 
before and after proceedings. 
All the equipment used in the culture room was previously sterilized by means of 
autoclaving, bleaching or 70% alcohol washing. All the solutions were filtered with 0.2 µM-
sized porous filters before usage while all proceedings were performed with gloves. 
 
 Primary cell cultures 
Primary cell cultures were obtained from lung biopsies obtained at Hospitais da 
Universidade de Coimbra (HUC). Different protocols were used to obtain viable cell cultures 
from the biopsies. 
Primary cultures of human bronchial fibroblasts and human bronchial epithelial cells 
were obtained from lung biopsies using both mechanical and chemical procedures. Care was 
taken to avoid biopsies containing alveolar parts (pneumocytes) as it is impossible to 
implement epithelial cell cultures from pneumocytes.  
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2.4.1.1. HUMAN BRONCHIAL FIBROBLASTS (HBF) PRIMARY CULTURES 
Mechanical method: tissue biopsies were washed with 1x PBS and dissected, under 
sterile conditions, with the help of a scalpel, into tiny bits (about 1 mm2). The tissue pieces 
were homogeneously placed in the surface of a T25 cell culture flask and a drop of FBS was 
placed on the top of each tissue sample to facilitate the attachment to the cell surface and to 
provide nutrients for attachment period. With a Pasteur pipette, the excess of serum was 
removed from the neighbours of the tissue fragments and the flask was turned upside down 
and placed in the CO2 incubator overnight. After this incubation period, 5 mL of DMEM/F12 
medium were added to the top of the flask and the flask was gently turned to its correct 
position allowing the tissue fragments to contact with the medium. Cells were expected to 
migrate from these explants in the next two weeks. 
 
Chemical method: also required biopsies dissection to obtain small pieces of tissue. The 
tiny tissue pieces were place into a 15 mL centrifuge tube containing pronase, a protease 
capable of cleaving cell-cell interactions, and left at 4°C temperature overnight to allow 
pronase to act. After the digestion, the tissue left unfragmented was removed with the help of 
a Pasteur pipette and the remaining cell suspension centrifuged for 5 minutes at 1200 rpm. 
The supernatant containing dead cells and pronase was removed and the pellet re-suspended 
in 5 mL DMEM/F12 medium. This cellular suspension was placed in a new T25 cell culture flask 
and fibroblasts were allowed to attachment to the surface for 4 hours. The supernatant 
containing epithelial cells (didn’t attach under such culture conditions) was removed and used 
to establish the human bronchial epithelial primary cell cultures. To the flask containing the 
attached fibroblasts, 5 mL of fresh DMEM/F12 were added and the cells allowed growing for 
approximately two weeks. Once a week half the volume of medium was replaced by fresh 
medium to give the cells fresh nutrients but avoiding the deprivation of cell-secreted growth 
factors. 
Once established, the cultures were maintained as described below in section 2.4.1.4. 
 
50 
 
 
2.4.1.2. HUMAN BRONCHIAL EPITHELIAL CELLS (HBEC)  PRIMARY 
CULTURES  
Just like HBF, primary cultures of HBEC were established out of the same biopsies using 
either mechanical or chemical protocols.  
The mechanical method was very similar to the one used to establish the primary 
cultures of fibroblasts, except that BEGM medium was used instead of the DMEM/F12 
medium.  
The chemical method used to establish the epithelial cultures profited the supernatant 
containing the cells that didn’t attach to the flask surface in DMEM/F12 after the 4 hours 
incubation. This supernatant was collected into a centrifuge tube and centrifuged for 5 
minutes at 1200 rpm to remove any dead cells. The pellet was re-suspended in BEGM and the 
mixture placed into T25 culture flasks previously coated with a matrix solution.  
To look for the best matrix, several experiments were performed. In the case of gelatine, 
1 mL of a 1 % gelatine solution was added to the T25 flask 2 to 72 hours prior the passage. 
During this period gelatine was allowed to polymerize in the CO2 incubator and the excess of 
gelatine solution was removed from the flask right before the addition of cells. 
For type I collagen coating, 1 mL of type I collagen solution was added to a T25 flask and 
200 µL for 24-well multiplate. The flasks or the multiwall plates were incubated for 30 minutes 
at room temperature, and the excess of collagen solution removed. The recipient was then 
transferred to an isolated box, with a piece of paper embedded in ammonia hydroxide to 
sterilize the recipient, for 15 minutes. The recipient was then washed with 1x PBS and cells 
were plated in its surface. 
The laminin and fibronectin coatings were done similarly to gelatine coating, with the 
addition of the laminin and fibronectin solutions previously prepared to the surface of the cell 
culture flasks. The flasks were incubated at 37°C for a minimum of 6 hours and the excess 
solution removed before cells were plated on the coated surfaces. 
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A mixture of the three supportive materials was also tested to mimic as much as possible 
the ECM. Once established the cultures, culture maintenance was performed as described 
below in section 2.4.1.4. 
 
 
2.4.1.3. BEAS-2B CELL LINE CULTURES 
 BEAS-2B cells were defrosted from stock quantities of this cell line and plated, on 
previously coated with gelatine 1% for a minimum of 2 hours, T75 flasks containing 13 mL of 
LHC-9 at 37°C. The medium was changed 24h after plating and cells were incubated at 37°C in 
an atmosphere with 5% of CO2 for a week until reaching confluence. Once reached, culture 
maintenance was performed as described below in section 2.4.1.4. 
 
 
2.4.1.4. CELL PASSAGE 
To guarantee the healthy preservation of the cultures, considering their growth rate 
and the fact that the cells’ phenotype can change once confluence is attained, any cell culture 
must be sub-cultured when they reach about 80% confluence. The minimum initial cell density 
used was 4000 cells/cm2. 
In anchorage-dependent cell cultures, once the ideal confluence was reached, the 
proceeding was straightforward. The cell medium was discarded and the flask washed with 1x 
PBS in order to remove the remnants of the cell medium. Following PBS removal, trypsin was 
added to detach cells’ from the supporting matrix, allowing cells to be collected. For trypsin’s 
maximum effect, the flask containing the cells and trypsin was incubated at 37°C for 10 
minutes, assuring that all cells were detached. 
After trypsinization, 5 mL of PBS were added to the flak to detach and collect cells and 
the suspension was then transferred to a centrifuge and centrifuged for 5 minutes at 1200 
rpm. The supernatant was discarded and the pellet ressuspended in the cells’ specific medium. 
A 10 µL aliquot of the cells’ suspension was used for cell counting with trypan blue. Once 
52 
 
evaluated the cell’s density, the volume containing the desired number of cells was transferred 
to a new flask and medium was added to get a total volume of 5 mL. 
 
 
2.4.1.5. CELL COUNTING  
0.4% Trypan blue was used to access the correct suspension cells’ density in order to 
transfer, to the culture flask, the exact number of cells. Trypan blue dye quickly enters the cells 
when the cell membrane is fragile. Inside the cells trypan blue gives the intracellular space a 
strong blue colour, allowing the assessment of the number of dead cells in the sample. 
Simultaneously, it is possible to evaluate the number of viable cells as they will not be stained 
and their cytoplasm is brighter. 
From the total cell suspension, a 10 µL sample was collected and mixed with a 10 µL 
sample of 0.4% trypan blue solution. From the 20 µL homogenous solution, 10 µL were 
collected and transferred to the haemocytometer. The number of viable cells was counted in 
each quadrant (in red in the Figure 2.1) and the average number of viable cells per quadrant 
was determined. 
Each haemocytometer quadrant has the virtual volume of 0.1 mm3 or 0.0001 mL and the 
haemocytometer contains only half of the cells’ volume removed from the original cell 
suspension as half of the volume is the trypan blue solution. Therefore, to calculate the viable 
cells’ concentration expressed as number of cells/volume (mL), the average number of cells 
were multiplied by 2 (due to concentration) and by 10000 (due to the solution volume in each 
quadrant). With this information it was possible to estimate the cells’ concentration in the 
original cell suspension and afterwards to calculate the volume to be transferred according to 
the number of cells required for each experiment. 
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Figure 2.1: Representation of haemocytometer relation of area/volume (A) and cell counting proceeding (B) 
(adapted from http://en.wikipedia.org/wiki/File:Haemocytometer_Grid.png). 
 
 
2.4.1.6. CELL FREEZING/UNFREEZING 
2.4.1.6.1. CELLS’ FREEZING 
Cells were preserved by freezing. In order to freeze cells, confluent T75 cell culture 
flasks (about 4 million cells) were used. Once obtained a confluent culture (see section 
2.4.1.4), the cells’ suspension in medium:FBS:DMSO ( 7:2:1 ratio) were placed in a cryogenic 
vial. The vials were subsequently transferred to an isopropanol-containing recipient at -80°C 
A 
B 
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for at least 4 hours, to allow a gradual decrease in temperature and, as such the cells’ gradual 
freezing, avoiding the formation of ice crystals due to the presence of DMSO. The vials were 
later transferred to a liquid nitrogen container at -120°C, where they were cryopreserved until 
needed. 
 
 
2.4.1.6.2. CELLS’ UNFREEZING 
Frozen cells can be reused in cell culture. To obtain cells, the frozen vials were 
removed from the container and unfrozen by manual friction. The vials content was then 
added to a previously warmed (37°C) T75 culture flask (pre-coated with gelatine in the case of 
epithelial cells) containing the appropriate cell culture medium. The flask was placed in the 
incubator and 24 hours after cells’ platting, medium was changed to remove the DMSO, which 
is toxic for cells at 37°C. Once the culture reached 80% confluence, cells were sub-cultured as 
indicated in section 2.4.1.4.  
 
 
2.5. ESTABLISHMENT OF Cr(VI) EXPOSURE CONDITIONS THAT INDUCED 
SENESCENCE ON HBF  
Aiming to establish the Cr(VI) exposure conditions (concentration and time) that would 
induce the emergence of a stable and irreversible senescent HBF phenotype, HBF cultures 
were only sub-cultivated till passage 13 to avoid replicative senescence and to mimic the 
fibroblasts in an adult lung. These cells were then regularly exposed, for extended periods of 
time, to different concentrations of Cr(VI), by adding different volumes of a 5 µM K2Cr2O7 
solution to the cells’ suspension in DMEM/F12. Cell medium was also regularly removed   and 
new medium containing Cr(VI) was added. The protocols varied in initial cell density, Cr(VI) 
concentration, frequency of medium change, interval of time to start the exposure and ability 
to undergo further cell passages until reaching the senescence, without compromising 
viability. In parallel, control experiments were performed but in the absence of Cr(VI). 
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To evaluate Cr(VI) exposure effects, the cells growth kinetics, morphologic and 
phenotypic change and senescent-associated-β-Galactosidase (SA-β-Gal) activity were 
monitored in control and Cr(VI) exposed cells using the MTT cell viability/proliferation assay, 
trypan blue, microscopic observation, immunocytochemistry, and the senescent-staining kit. 
 
 
2.6. CO-CULTURES 
To perform the co-cultures, 6-well multiwall plates were used. In each well, fibroblasts 
were seeded at an initial cell density of 2x104 cell/cm2 in DMEM/F12, in a total volume of 2 mL 
per well. For 4 weeks the cells were treated with either 0.25 or 0.5 µM Cr(VI), changing the 
medium every two days until cells’ reached the senescent state. Afterwards, 1% gelatine 
coated transwells were placed on each well, allowing the fibroblasts’ cell medium to be in 
direct contact with the bottom part of the transwell. This allowed the cells’ secreted factors to 
be in contact with the BEAS-2B cultivated on the upper compartment of the transwells, 
previously coated with gelatine. LHC-9 medium was used to cultivate the BEAS-2B plated at an 
initial cell density of 4.5x104 cell/cm2 in the transwell compartment, as was done by Chanson’s 
group, as well as other groups [Wiszniewski et al., 2006; Pohl et al., 2009]. Total volume of 
medium of each specific compartment was changed every three days for three to four weeks 
Control experiments were performed using Cr(VI)-untreated HBF and BEAS-2B seeded in 
their respective compartments in the absence of Cr(VI) insults. Additionally, Cr(VI) senescent 
fibroblasts and BEAS-2B were cultivated in presence of 0.25 µM and 0.5 µM concentration of 
Cr(VI), with the medium changed every 3 days.  
 
 
2.7. CELLS’ VIABILITY EVALUATION – MTT ASSAY 
The MTT assay is a colorimetric assay that quantifies the presence of mitochondrial 
dehydrogenises in cells. In this assay cleavage of the MTT structure by mitochondrial 
dehydrogenates and cellular reductases allows the quantification of cells’ viability by 
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measuring the absorbance in a 96-well multiplate reader of the purple formazan solutions, 
obtained following solubilisation of formazan crystals. 
In order to fulfil this objective, the cell medium was removed and the 0.5 mg/mL MTT 
solution was placed in contact with the cells. The volume of MTT solution needed for any 
result is 75% of the cell culture medium. The cells were incubated for 3 hours at 37 °C at 5% 
CO2 and, afterwards, the solution was removed from the wells, leaving the formazan crystals 
intact. The crystals were then dissolved with acidic isopropanol, using half of original cell 
medium volume (e.g. in case of 1 mL of DMEM/F12, 0.5 mL of medium was preserved). The 
resultant coloured solution was transferred to a 96-well multiwell, using 100 µL per well, with 
the absorbance being read in a multiplate reader, with a reference wavelength of 620 nm and 
a reading wavelength of 570 nm. The experiments were always done in comparison to a 
standard curve considering the initial cell density in order to obtain an estimative of cells’ 
proliferation. 
 
 
2.8. CELL’S MORPHOLOGY AND GROWTH PATTERN EVALUATION 
Cells’ morphology and growth pattern were continuously monitored by microscopic 
observation. Photographs were obtained using an Olympus T-100 digital camera. 
 
 
2.9. SENESCENT PHENOTYPE EVALUATION 
To this end a senescent cell staining kit was used. The cells, in 12-well plates were fixed 
for 6-7 minutes in the 1x fixation buffer solution, prepared from the 10x fixation buffer 
solution by dilution with ultrapure water. Following removal of the fixation buffer, a mixture of 
40 μL of the 10x staining solution, 5 μL of reagent B, 5 μL of reagent C, 10 μL of X-Gal solution 
and 340 μL of ultrapure water was added to each well. The plates were sealed with parafilm 
and incubated at 37°C for 5 hours. Cells were observed by microscopy and images were 
recorded with the aid of a Olympus T-100 digital camera. 
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2.10. IMMUNOCYTOCHEMISTRY 
For immunocytochemistry analysis fibroblast were grown on top of slides under 
exposure conditions (0.25 or 0.50 µM Cr(VI) and exposure time) used to induce fibroblasts’ 
senescence. The cell medium was removed and cells were washed 3 times with 1x PBS and 
then fixed in 95% ethanol. 
Afterwards, the endogenous peroxidase activity was quenched using 15 minutes 
incubation in 3% diluted hydrogen peroxide (H2O2). For blocking the nonspecific binding with 
primary antibodies, slides were first dipped in Ultra V Block, from the Ultra Vision Kit, from 5 
minutes. Primary antibodies against cytokeratin (MNF116) at a dilution of 1:50, Vimentin at a 
dilution of 1:200, anti-human smooth muscle actin (-SMA) at a dilution of 1/200, E-Cadherin  
at a dilution 1:25, were applied to the sections and incubated at room temperature for 30 
minutes in the case of the first three antibodies and for 60 minutes E-Cadherin. The slides 
were then washed with 1x PBS from the Ultra Vision Kit, and incubated 15 minutes with biotin-
labeled secondary antibody, commercialized as part of the Ultra Vision Kit. Primary antibody 
binding was localized using peroxidase-conjugated streptavidin (Ultra Vision Kit) and 3,3-
diaminobenzidine tetrahydrochloride (DAB) was used as chromogen, according to 
manufacturer’s instructions. Hematoxylin was used to counter stain the slides which were then 
dehydrated and mounted. 
For positive controls, different tissues were compared to, using smooth muscle for α-
actin staining, colon for vimentin, tonsils for E-Cadherin and epithelial cells for cytokeratin 
(MNF-116).
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3.1. HUMAN BRONCHIAL FIBROBLASTS (HBF) PRIMARY CULTURES  
During the course of this project several human primary cultures were established 
from lung biopsies. The efficiency of the protocols varied considerably, mainly due to 
impossibility of controlling the lung location from where the biopsies were extracted.  
Using the mechanic protocol, after one week cells were able to outgrow from the 
explants. The primary cultures of HBF established with this protocol remained viable for one 
month and could stand viable following cryopreservation (Figure 3.1). However, the cultures 
were not homogeneous and it was possible to identify morphologically different cellular sub-
populations. These findings emphasized the fact that HBF cultures greatly depend on the 
original tissue surrounding environment, as different cellular phenotypes can be present in 
biopsies acquired from the same patient. 
As to the chemical protocol, after one week in culture cells were able to attach the flask 
surface and to form colonies. Culture confluence was obtained, in some cases, after two 
weeks, while in others was up to one month (Figure 3.2). This large variance was again related 
to the location of the tissue in the lung and the abundance of connective tissue. 
Both protocols used to implement HBF cultures were equally effective, with the chemical 
protocol being slightly more efficient (one additional cell culture was established) (Table 3.1). 
 
Table 3.1: Viable primary HBF cultures obtained by the mechanical and the chemical protocols. 
Mechanical Protocol Chemical Protocol 
PN46-D3 Fibro.PN2 
PN44-G PN2 
PN44-H Fibroblastos-14 
PT46-C2 Fibroblastos-13 
PT44-B Fibroblastos-11 
PT44-B1 Fibroblastos-10 
 Geneva1 
 
62 
 
Figure 3.1: Representative images of the morphology of HBF cultures obtained using the mechanical protocol: 
PN44-G (A), PN46-D3 (B), PT44-B1 (C), PT44-B (D), all at passage 1 and magnified 100X. 
Figure 3.2: Representative images of the morphology of HBF cultures obtained using of chemical protocol: Geneva1 
at passage 4 (A) and Fibro.PN2 (B), Fibroblastos-13 (C) and Fibroblastos-11 (D) at passage 1 and magnified 100X. 
A B 
D C 
D 
A B 
C 
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3.2. PRIMARY CULTURES OF HUMAN BRONCHIAL EPITHELIAL CELLS (HBEC)  
Regarding the HBEC primary cultures, both protocols were tested but the chemical 
protocol was unsuccessful as no primary cultures were able to grow out of the pronase 
digested tissues. 
Using the mechanical protocol it was possible to obtain some primary cultures of 
epithelial cells that grew out of the lung explants (Figure 3.3). The success of this protocol was 
far from 100% as only in one third of total number of flasks epithelial cultures were 
established. One possible explanation is the lung location from where the biopsies were 
collected as diversity of cell types and their respective abundance varies with the zone location 
in the lung. Regarding this, regions of alveolar sacs contain a great quantity of pneumocytes 
while in the primary bronchial segment a great deal of goblet cells can be found [Figure 1.1]. 
Overall, it was possible to establish six epithelial primary cultures. 
 
Table 3.2: The attained HBEC cultures using the mechanical protocol. 
Mechanical Protocol 
3 
4 A 
7 A 
10 
11 
 
Unfortunately, none of the HBEC cultures was able to be maintained after 4 weeks in 
culture. Confluence was never obtained even by keeping medium quality by changing 
frequently the medium. Additionally, following the trypsinization process, only one of the 
trypsinized cells was able to re-attach to the gelatin matrix-coated surface of the culture flasks. 
The remaining attempts to use different matrixes such as collagen type I, fibronectin and 
laminin, either isolated or combined, revealed unsuccessful. These results confirmed that the 
lack of a real supportive layer, such as fibroblasts, like happens in  vivo in the bronchus, 
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rendered very difficult the development of a confluent epithelial layer, as the cells’ 
proliferation was very reduced, being dependent of growth factors secreted from the 
connective tissue, namely integrins and collagen. 
Thus, as the alternatives to obtain stable primary cultures of HBEC failed, the commercial 
human bronchial epithelial cell line BEAS-2B was used instead in the co-culture experiments 
with Cr(VI)-induced senescent fibroblasts. 
Figure 3.3: Representative images of the morphology of epithelial cell cultures obtained using the mechanical 
protocol: Culture 3 (A), 4A (B), 10 (C), 7A (D), all magnified 100X. 
 
 
3.3. Cr(VI) EXPOSURE CONDITIONS THAT INDUCE SENESCENCE ON HUMAN 
BRONCHIAL FIBROBLASTS (HBF)  
Several experiments were performed to induce an irreversible state of senescence on 
fibroblasts. For this purpose several primary cultures of HBF were used and their respective 
passage number is illustrated in Table 3.3. 
A B 
D C 
65 
 
The primary cultures of HBF used were: HFP6, CBR, previously prepared and used from 
passage 8 and passage 3 onwards respectively, as well as Geneva1, used from passage 4 
onwards. 
 
Table 3.3: Primary HBF cultures used in the senescence experiments.  
Primary 
Culture 
Starting 
Passage 
Final 
Passage 
HFP6 8 17 
CBR 3 12 
Geneva1 4 6 
 
 
3.3.1. DETERMINATION OF THE Cr(VI) EXPOSURE CONDITIONS THAT INDUCE 
GROWTH ARREST 
Initially, the experiments with HFP6 bronchial fibroblasts were performed to evaluate: 
(i) time and Cr(VI) concentrations that would induced morphologic changes associated with 
the emergence of the senescent phenotype; (ii) the ideal cell density to start up the cultures in 
order to achieve, at the end of one week in culture, a cell density that would avoid quiescence 
as result of confluence; (iii) a cell density that would give rise to enough cells to cover the 
bottom of transwells to be used in the co-cultures.   
Based on the work from the Lab [Rodrigues et al., 2009; Costa et al., 2011], the 
concentrations of Cr(VI) tested ranged from 0.1 to 4 µM, as Cr(VI) exposures < 1 µM induced 
proliferation of BEAS-2B, while 1 µM Cr(VI) induced cells’ malignant transformation. 
Conversely, concentrations > 1 µM Cr(VI) induced BEAS-2B cells’ death [Rodrigues et al., 2009; 
Costa et al., 2011]. 
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Table 3.4: Experiments using HPF6 passage 9 and 10 fibroblasts. In the experiments with HFP6 passage 9, Cr(VI) was 
added on day 1 after plating, and cells were cultured for additional 3 days. In the experiments with HFP6 passage 
10, Cr(VI) was added on day 3 after plating and cells were cultured for additional 4 days. Control experiments were 
performed similarly but in the absence of Cr(VI). 
 
 As illustrated in Table 3.4 in the experiments using HFP6 passage 9, Cr(VI) was added one 
day after plating, and cells were cultivated for additional 3 days without changing the medium. 
In the experiments with HFP6 passage 10, Cr(VI) was added on day 3 after plating and cells 
were cultivated for additional 4 days without changing the medium. 
Figure 3.4 illustrates the morphological changes observed in HFP6 passage 9 cells, 3 days 
exposed to 2 µM Cr(VI). The images revealed that Cr(VI) induced changes on both the cells’ 
number and morphology, as cells exposed to the oxyanion display a rounder shape. Lower 
Cr(VI) concentrations induced less visible effects as revealed in Figure 3.4. 
 
HFP6 
Passage 
Number 
Cell 
Density 
(cell/cm
2
) 
[Cr(VI)] 
(µM) 
Days 
0 1 2 3 4 5 6 7 
9 50000 
0.1 
Plating 
Addition 
of Cr(VI) 
   
 
0.5    
1    
2    
10 50000 
0.1 
Plating 
  
Addition 
of Cr(VI) 
    
0.5       
1       
2       
4       
A B 
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Figure 3.4: Representative images of the morphology of 
HFP6 passage 9 cells. In the case of Cr(VI) exposed 
cultures images were taken 3 days after Cr(VI) addition, 
Control images were taken simultaneously. Control (A), 
0.1 µM (B), 0.5 µM (C), 1 µM (D), 2 µM (E), all magnified 
100X. 
 
 
 
 
As to the experiments performed with HFP6 passage 10, even though Cr(VI) was added 
when cells were already at the exponential growth phase and, as such, more resistant, the 
longer exposure time  (4 days) to higher Cr(VI) concentrations (2 and 4 µM) induced some cell 
death. The cell death can be seen by the increasing amount of floating round cells in cultures 
(brighter round spots on Figure 3.5), as well as a rounder and darker tone to the cells in the 
same figure. As illustrated in Figure 3.5, 4 days exposure to 1 µM Cr(VI) induced, in HFP6 
passage 10 fibroblasts, morphologic changes similar to the ones observed in HFP6 passage 9 
fibroblasts exposed 3 days to 2 µM Cr(VI) (Figure 3.4). 
 
B 
C D 
E 
A 
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Figure 3.5: Representative images of the morphology of HFP6, passage 10 cells, at day 7 in culture. In the case of 
Cr(VI) exposed cultures images were taken 4 days after Cr(VI) addition. Control (A), 0.1 µM (B), 0.5 µM (C), 1 µM (D), 
2 µM (E), 4 µM (F), all magnified 100X. 
 
As Cr(VI) concentration decreases along time in culture, due to Cr(VI) cellular uptake it 
was decided to frequently replace the medium by fresh one with Cr(VI). Doing so the main goal 
was to evaluate whether exposing cells to a more uniform Cr(VI) concentration would induce 
more distinct changes.  
Additionally, the cell density was reduced to 20000 cells/cm2, as these would be the ideal 
cell density to be used in the co-cultures experiments accordingly to Chanson and 
A B 
D C 
E F 
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collaborators [Wiszniewski et al., 2006]. Moreover, as results revealed, increasing the cell 
density would lead to early to confluence.  
Table 3.5: Experiments using HPF6 fibroblasts, passage 11. In Condition 1 experiments, Cr(VI) was added just once 
at day 1. In Condition 2, experiments the medium containing Cr(VI) was replaced on day 2 by fresh medium with 
Cr(VI). In Condition 3 experiments the medium containing Cr(VI) was replaced on days 2 and 3, by fresh medium 
with Cr(VI). In Conditions 4-6 experiments the medium replacement schedule, after the first Cr(VI) addition, was as 
in previous Conditions 1-3 experiments. Control experiments were performed similarly but in the absence of Cr(VI).  
Morphological changes were observed at day 8. 
Experiment   
Passage 
Number 
Cell 
Density 
(cell/cm2) 
[Cr(VI)] 
(µM) 
Days 
0 1 2 3 4 5 6 7 
Condition 1 
(Cr(VI) was 
added once 24h 
after plating) 
11 20000 
  
Plating 
Addition 
of Cr(VI) 
            
Condition 2 
(As in Condition 1 
but medium was 
replaced once) 
11 20000 
0.5  
Addition 
of Cr(VI) 
Addition 
of Cr(VI) 
          
Condition 3 
(As in Condition 1 
but medium was 
replaced twice) 
11 20000 1 
Addition 
of Cr(VI) 
Addition 
of Cr(VI) 
Addition 
of Cr(VI) 
        
Condition 4 
(Cr(VI) was 
added once 48 h 
after plating) 
11 20000 
2 
  
Addition 
of Cr(VI) 
          
Condition 5 
(As in Condition 4 
but medium was 
replaced once) 
11 20000 
  
  
Addition 
of Cr(VI) 
Addition 
of Cr(VI) 
        
Condition 6 
(As in Condition 4 
but medium was 
replaced twice) 
11 20000 
  
  
Addition 
of Cr(VI) 
Addition 
of Cr(VI) 
Addition 
of Cr(VI) 
      
 
In these experiments, cell death was observed in both 1 µM and 2 µM Cr(VI)-exposed 
HFP6 (passage 11). These results are easily explained considering that the cells’ density was 
less than half the density used in previous experiments and, consequently, the Cr(VI) 
concentration each cell was exposed to, almost duplicate. The morphologic changes, more 
rounded shaped cells, and the decreased cellular proliferation ability (as evaluated by trypan 
blue) observed in 0.5 µM Cr(VI)-exposed HFP6 cells (passage 11), were similar to the changes 
observed in previous experiments with 1 µM Cr(VI)-exposed HPF6 passage 10 (Figure 3.5 D) 
(Figure 3.6). 
Nevertheless, it could be observed that a single addition of 1 µM of Cr(VI), 48h after cells’ 
plating (Condition 4), did not induce cell death but, morphologic changes similar to the ones 
observed 4 days after 1 µM Cr(VI) addition to HPF6 passage 10 cells (Figures 3.5,D and 3.6, 
F,G). Similar effects were observed in HPF6 passage 11 fibroblasts cultures, at day 7, following 
repetitive exposure to 0.5 µM Cr(VI) (Condition 3 experiments) (Figure 3.6, C). 
A B 
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Figure 3.6: Representative images of the morphology 
of HFP6 passage 11 cells, at day 7 in culture. Control 
(A), Condition 2 - 0.5 µM (B), Condition 3 - 0.5 µM (C), 
Condition 4 - 0.5 µM (E) and 1 µM (F,G), Condition 6 - 
0.5 µM (D). 
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G 
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As revealed by the trypan blue assay and illustrated in Figure 3.7, HFP6 passage 11 
cultures exposed to 0.5 µM Cr(VI), except Condition 3 exposed cells, proliferate after a week in 
culture. Most important was the finding that for 1 µM Cr(VI) Condition 4, the change in HFP6 
passage 11 cells’ morphology and the constant cell number along the 7 days cultivation 
suggested the emergence of a senescent-like phenotype (Figure 3.6). 
Figure 3.7: Cr(VI) effects on HFP6 passage 11 cells’ proliferation. The number of cells, at day 7 in culture, was 
evaluated by trypan blue assay. The results, expressed as the ratio of final to initial cells’ number in each culture, are 
the mean ± SD of at least three experiments carried out in triplicate.  
 
All these results have showed that there is a great dependence on cell density, resulting 
of which the Cr(VI)-exposure effect will vary. Also, the time of addition of Cr(VI) is also an 
important variable, as cell density will increase with time, therefore diminishing the Cr(VI) 
effect. Also, passage number is presented as a variable due to progressive loss of replication 
capacity as senescence is an aging-related process. 
In order to evaluate whether the Cr(VI) effects were dependent upon HFP6 cells’ passage 
number, the experiments were repeated [except conditions 5 and 6, as well as 2 µM Cr(VI) 
exposures] using HFP6  passage 13 fibroblasts. Cells’ counting was performed the day after the 
last Cr(VI) addition and at day 7 in culture (Table 3.6) using the trypan blue method. 
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Table 3.6: Experiments using HPF6 passage 13. In Condition 1 experiments Cr(VI) was added just once at day 1. In 
Condition 2 experiments the medium containing Cr(VI) was replaced on day 2 by fresh medium with Cr(VI). In 
Condition 3 experiments the medium containing Cr(VI) was replaced on days 2 and 3, by fresh medium with Cr(VI). 
In Conditions 4 experiments Cr(VI) was added just once at day 2. Control experiments were performed similarly but 
in the absence of Cr(VI). Morphological changes were observed at day 7. 
Experiment  
Passage 
Number 
Cell 
Density 
(cell/cm2) 
[Cr(VI)] 
(µM) 
Days 
0 1 2 3 4 5 6 7 
Condition 1 
(Cr(VI) was added 
once 24h after 
plating) 
13 20000 
  
Plating 
Addition 
of Cr(VI) 
Cell 
Count 
        
Cell 
Count 
Condition 2 
(As in Condition 1 
but medium was 
replaced once) 
13 20000 
0.5  
Addition 
of Cr(VI) 
Addition 
of Cr(VI) 
Cell 
Count 
      
Cell 
Count 
Condition 3 
(As in Condition 1 
but medium was 
replaced twice) 
13 20000 
1 
Addition 
of Cr(VI) 
Addition 
of Cr(VI) 
Addition 
of Cr(VI) 
Cell 
Count 
    
Cell 
Count 
Condition 4 
(Cr(VI) was added 
once 48 h after 
plating)  
13 20000 
  
  
Addition 
of Cr(VI) 
Cell 
Count 
      
Cell 
Count 
 
The addition of Cr(VI) 24h after cells’ plating (Conditions 1 and 3) lead to extensive cell 
death, more pronounced under Condition 3 experimental conditions (Table 3.7). The surviving 
cells gained rounded-like shape morphology 72h after being exposed to Cr(VI) (Figure 3.8). 
Under Conditions 4 experimental conditions (addition of Cr(VI) 48 hours after plating), 
decreased cell death was observed in HFP6 passage 13 fibroblasts exposed to 1 µM Cr(VI) and 
for  0.5 µM Cr(VI) exposures the number of cells remained constant since Cr(VI) addition (Table 
3.7).  In spite of the constant cell number cells lose their spindled-like shape and very quickly 
gained flat rounded shape morphology (Figure 3.8). 
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Table 3.7: Experiments using HPF6 passage 13. Control experiments were performed in the absence of Cr(VI). Cells’ 
counting was performed 24 hours after Cr(VI) addition and at day 8 in culture. The results are expressed as the 
ration of initial to final cells’ number, and represent the mean ± SD of at least three experiments carried out in 
triplicate. 
As illustrated in Table 3.7, the addition of Cr(VI) 24 hours after cells’ plating lead to 
extensive  cell death, while the addition of Cr(VI) 48 hours after plating lead to growth arrest, 
this one more pronounced in the 0.5 µM exposures. 
 
Figure 3.8: Representative images of the morphology of 
HFP6 passage 13 cells, day 8 in culture, Condition 4 
exposure regimen. Control (A), 0.5 µM (B), and 1 µM 
(C), all magnified 100X. 
 
 
 
Experiment 
Passage 
Number 
Cell 
Density 
(cell/cm2) 
[Cr(VI)] 
(µM) 
Ratio of Initial to Final Cells’ Number  
After Cr(VI) 
Exposure 
SD 
value 
One Week 
of Culture 
SD 
value 
Δ 
Ratio 
Condition 1 
13 20000 
Control 2,71 0,38 5,93 0,80 3,22 
(Cr(VI) was added once 24h 
after plating 
0.5 2,04 0,05 0,00 0,00 -2,04 
1 0,81 0,15 0,01 0,00 -0,80 
Condition 2 
13 20000 
Control 3,57 0,33 5,62 0,83 2,05 
(As in Condition 1 but 
medium was replaced once) 
0.5 0,60 0,15 0,36 0,00 -0,24 
1 0,29 0,00 0,01 0,00 -0,28 
Condition 3 
13 20000 
Control 4,38 0,41 6,74 0,73 2,36 
(As in Condition 1 but 
medium was replaced twice) 
0.5 0,48 0,11 0,19 0,15 -0,29 
1 0,14 0,00 0,07 0,00 -0,07 
Condition 4 
13 20000 
Control 3,40 0,15 5,24 0,69 1,84 
(Cr(VI) was added once 48 h 
after plating) 
0.5 3,05 0,32 3,36 0,00 0,31 
1 2,88 0,22 2,33 0,30 -0,55 
B 
A 
C 
B A B 
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These last results confirm that there was a great dependence on cell passage, as 
concentrations previously non-lethal had become lethal after just two cell passages, especially 
in conditions when Cr(VI) is added just 24h after plating. This particular result can indicate that 
cell-adhesion was the most affected process by passage number increase, as cells were easily 
dettached and started floating after Cr(VI) exposure. 
 
 
3.3.2. DETERMINATION OF THE Cr(VI) EXPOSURE CONDITIONS THAT 
INDUCED SENESCENCE 
Accordingly to Chanson and collaborators [Wiszniewski et al., 2006], human airway 
epithelial cells (HAEC) co-cultivated with HBF differentiate into ciliated cells. For this to 
happen, HAEC were grown for four weeks in transwells undercoated with fibroblasts under 
submerged conditions with the growth medium being refreshed every 2 days [Wiszniewski et 
al., 2006]. 
To evaluate whether Cr(VI)-induced senescent HBF would induce transformation (and not 
differentiation) on bronchial epithelial cells it was imperative to find which Cr(VI) exposure 
conditions would induce HBF senescence and whether this senescent cells would be able to 
sustain continuous long-term exposure (four weeks) and remain senescent.  
Having in mind that 0.5 µM Cr(VI), added 48 hours after fibroblasts plating, induced 
growth arrest and morphologic changes that suggested the emergence of cells with 
senescence phenotype (section 3.3.1), primary cultures of HBF, identified as CBR (passage 4 
and 5) were exposed, 48 hours after plating, to 0.05 to 0.75 µM Cr(VI) with medium changed 
every two days for four weeks (Tables 3.8 and 3.9). Cells’ viability asnd number, evaluated by 
the MTT  and trypan blue assays, was determined every two or four days of culture to know 
whether cells’ were able to sustain long-term Cr(VI) insults, without reversing the senescent 
phenotype or dying. Experiments were also performed with CBR passage 5 fibroblasts to 
evaluate whether passage number was interfering with the results (Table 3.9). 
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Table 3.8: Experiments using CBR passage 4 fibroblasts. In all experiments Cr(VI) was added 48 days after cells’ 
plating and the medium renewed every two days. Control experiments were performed similarly but in the absence 
of Cr(VI). Cells’ viability was evaluated by MTT every two days. 
Experiment  
[Cr(VI)] 
(µM) 
Passage 
Number 
Cell Density 
(cell/cm2) 
Days 
0 1 2 3 4 5 6 7 8 
Control 4  20000 
Plating 
  Cell 
Viability 
  Cell 
Viability 
  Cell 
Viability 
  Cell 
Viability 
        
0.05 4  20000 
  
Addition 
of Cr(VI) 
  
Addition 
of Cr(VI) 
  
Addition 
of Cr(VI) 
  
Cell 
Viability 
  
Cell 
Viability 
  
Cell 
Viability 
  
Cell 
Viability 
  
0.1 4  20000 
  
Addition 
of Cr(VI) 
  
Addition 
of Cr(VI) 
  
Addition 
of Cr(VI) 
  
Cell 
Viability 
  
Cell 
Viability 
  
Cell 
Viability 
  
Cell 
Viability 
  
0.25 4  20000 
  
Addition 
of Cr(VI) 
  
Addition 
of Cr(VI) 
  
Addition 
of Cr(VI) 
  
Cell 
Viability 
  
Cell 
Viability 
  
Cell 
Viability 
  
Cell 
Viability 
  
0.5 4  20000 
  
Addition 
of Cr(VI) 
  
Addition 
of Cr(VI) 
  
Addition 
of Cr(VI) 
  
Cell 
Viability 
  
Cell 
Viability 
  
Cell 
Viability 
  
Cell 
Viability 
  
0.75 4  20000 
  
Addition 
of Cr(VI) 
 
Addition 
of Cr(VI) 
 
Addition 
of Cr(VI) 
  
Cell 
Viability 
  
Cell 
Viability 
 
Cell 
Viability 
 
Cell 
Viability 
  
 
Table 3.9: Experiments using CBR passage 5 fibroblasts. In all experiments Cr(VI) was added 48 days after cells’ 
plating and the medium renewed every two days. Control experiments were performed similarly but in the absence 
of Cr(VI). Cells’ viability and number were evaluated by MTT and trypan blue assays every two days . 
Experiment  
[Cr(VI)] 
(µM) 
Passage 
Number 
Cell Density 
(cell/cm2) 
Days 
0 1 2 3 4 5 6 7 8 
Control 5 20000 
Plating 
  Cell 
Viability 
  Cell 
Viability 
  Cell 
Viability 
  Cell 
Viability 
        
0.1 5 20000 
  
Addition 
of Cr(VI) 
  
Addition 
of Cr(VI) 
  
Addition 
of Cr(VI) 
  
Cell 
Viability 
  
Cell 
Viability 
  
Cell 
Viability 
  
Cell 
Viability 
  
0.25 5 20000 
  
Addition 
of Cr(VI) 
  
Addition 
of Cr(VI) 
  
Addition 
of Cr(VI) 
  
Cell 
Viability 
  
Cell 
Viability 
  
Cell 
Viability 
  
Cell 
Viability 
  
0.5 5 20000 
  
Addition 
of Cr(VI) 
  
Addition 
of Cr(VI) 
  
Addition 
of Cr(VI) 
  
Cell 
Viability 
  
Cell 
Viability 
  
Cell 
Viability 
  
Cell 
Viability 
  
 
As illustrated in Figures 3.9 and 3.10, cells continuously exposed to 0.5 µM did not 
proliferate, visibly delaying their growth when compared to lower Cr(VI) concentration 
exposures. Conversely, cell death was observed in cultures exposed to 0.75 µM Cr(VI) (Figure 
3.9). As shown in Figures 3.9 and 3.10 low passage number cells’ portrayed similar behaviour. 
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Figure 3.9: Cr(VI) effects on in CBR passage 4 cells viability. The cell viabilty in culture was evaluated by MTT assay 
every two days. The results, expressed as the ratio of final to initial cells’ viability are the mean ± SD of at least 
experiments carried out in triplicate.  
 
Table 3.10: Cr(VI) effects on in CBR passage 4 cells viability. The cell viabilty in culture was evaluated by MTT assay 
every two days. The results, expressed as the Ratio of final to initial cells’ viability are the mean ± SD of at least 
experiments carried out in triplicate. 
 
[Cr(VI)] 
(µM) 
Passage 
Number 
Cell 
Density 
(cell/cm
2
) 
Days 
Ratio of 
Final to 
Initial 
cells’ 
Viability  
2 
SD 
Value 
4 
SD 
Value 
6 
SD 
Value 
8 
SD 
Value 
Control 4 20000 1,25 0,58 2,90 0,27 5,65 0,89 10,90 1,79 
0.05 4 20000 1,50 0,55 4,30 1,99 5,85 1,48 8,10 1,88 
0.1 4 20000 1,60 0,48 4,00 1,08 4,65 0,65 8,60 2,16 
0.25 4 20000 1,70 0,78 3,40 0,45 3,95 0,65 6,70 1,87 
0.5 4 20000 2,10 0,69 2,70 0,65 2,30 2,96 2,90 3,21 
0.75 4 20000 ND ND 3,00 1,24 1,55 3,03 0,58 2,29 
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Figure 3.10:  Cr(VI) effects on in CBR passage 5 cells viability. The cell viability in culture was evaluated by MTT assay 
every two days. The results, expressed as the ratio of final to initial cells’ viability are the mean ± SD of at least 
experiments carried out in triplicate.  
 
Table 3.11: Cr(VI) effects on in CBR passage 5 cells viability. The cell viability in culture was evaluated by MTT assay 
every two days. The results, expressed as the ratio of final to initial cells’ viability are the mean ± SD of at least 
experiments carried out in triplicate. 
[Cr(VI)] 
(µM) 
Passage 
Number 
Cell 
Density 
(cell/cm
2
) 
Days 
Ratio 
of Final 
to 
Initial 
cells’ 
Viabilit
y  
2 
SD 
Value 
4 
SD 
Value 
6 
SD 
Value 
8 
SD 
Value 
Control 5 20000 1,50 0,37 2,69 0,45 3,84 0,99 5,34 0,76 
0.1 5 20000 1,50 0,37 2,31 0,80 3,59 0,57 4,18 0,56 
0.25 5 20000 1,50 0,37 2,21 0,18 3,22 1,07 3,79 1,31 
0.5 5 20000 1,50 0,37 1,75 0,63 1,97 0,80 1,90 1,00 
 
Finally, four week-long experiments were performed using 0.25 and 0.5 µM Cr(VI) 
concentrations and CBR passage 8 cells. Cr(VI) containing medium was renewed every two 
days (Table 3.12). Additionally, experiments without Cr(VI) [wo.Cr(VI)] were carried out to 
evaluated if in the absence of a continuous Cr(VI) insult the emergent phenotype would 
reverse. To this end, cells were exposed to 0.5 µM Cr(VI), with constant Cr(VI) containing 
medium renewal every two days for a week. Thereafter, medium without Cr(VI) was added 
and renewed every two days for the next three weeks (Table 3.12). Senescence-associated β-
galactosidase staining kit was used to evaluate the emergence of senescence phenotype along 
cultures and the senescence levels. 
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Table 3.12: Experiments using CBR passage 8 cells. In all experiments Cr(VI) was added 48 hours after cells’ plating 
and the medium renewed every two days along four weeks except in wo. Cr(VI) cultures which were exposed to 
Cr(VI) just one week as described in Materials and Methods.  
Passage 
Number 
8 8 8 8 
Cell Density 
(cell/cm2) 
20000 20000 20000 20000 
[Cr(VI)] 
(µM) 
Control 0.25 µM 0.5 µM wo. Cr(VI) 
Days 
0 Plating 
1     
2  Addition of Cr(VI) Addition of Cr(VI) Addition of Cr(VI) 
3     
4  Addition of Cr(VI) Addition of Cr(VI) Addition of Cr(VI) 
5     
6  Addition of Cr(VI) Addition of Cr(VI) Addition of Cr(VI) 
7     
8  Addition of Cr(VI) Addition of Cr(VI)  
9     
10  Addition of Cr(VI) Addition of Cr(VI)  
11     
12  Addition of Cr(VI) Addition of Cr(VI)  
13     
14  Addition of Cr(VI) Addition of Cr(VI)  
15     
16  Addition of Cr(VI) Addition of Cr(VI)  
17     
18  Addition of Cr(VI) Addition of Cr(VI)  
19     
20  Addition of Cr(VI) Addition of Cr(VI)  
21     
22  Addition of Cr(VI) Addition of Cr(VI)  
23     
24  Addition of Cr(VI) Addition of Cr(VI)  
25     
26  Addition of Cr(VI) Addition of Cr(VI)  
27     
28  Addition of Cr(VI) Addition of Cr(VI)  
29     
30  Addition of Cr(VI) Addition of Cr(VI)  
31     
32 Evaluation of Senescence by β-galactosidase staining 
 
 
A B 
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Figure 3.11: Representative images of the morphology of 
CBR passage 8 cells, day 32 in culture. Control (A), 0.25 
µM (B, C), 0.5 µM (D, E, F) and wo.Cr(VI) (G), all magnified 
100X. 
 
 
 
 
 
G 
D 
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As can be observed on Figure 3.11, cells exposed constantly for four weeks to 0.5 µM 
Cr(VI) had preponderant rounded-shape morphology, disorganized structure and noticeably 
less confluence. These characteristics could also be seen on 0.25 µM Cr(VI)-exposed cells, 
although in a minor extent. 
An interesting effect could be observed on wo.Cr(VI) cells. As images on Figure 3.10 
revealed, two different cellular sub-populations are visibly co-existing: round-like, possibly 
senescent cells, on a lower layer and spindled-like, apparently normal, cells on a top layer. The 
morphologic phenotypes co-existence may suggest that senescent cells, on the top layer, are 
reversing their phenotype and so recovering the normal phenotype, because the Cr(VI)-
pressure was removed. This hypothesis was further supported on evaluating the cells’ viability 
ratio, obtained throught MTT assay (Figure 3.12). 
 
Figure 3.12: Cr(VI) effects on in CBR passage 8 cells viability. Cr(VI) addition was carried out 48 hours after cells’ 
plating and the medium replaced every two days along 32 days culture, except for wo.Cr(VI) cell cultures, whose 
medium contained 0.5 µM Cr(VI) during one week, followed by medium without Cr(VI) during the next three weeks. 
Control experiments were performed similarly but in the absence of Cr(VI). Cells’ viability in culture, was evaluated 
by MTT assay every four days. The results, expressed as the ratio of final to initial cells’ viability are the mean ± SD 
of at least experiments carried out in triplicated. 
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Table 3.13: Cr(VI) effects on in CBR passage 8 cells viability. Cr(VI) addition was carried out 48 hours after cells’ 
plating and the medium replaced every two days along 32 days culture, except for wo.Cr(VI) cell cultures, whose 
medium contained 0.5 µM Cr(VI) during one week, followed by medium without Cr(VI) during the next three weeks. 
Control experiments were performed similarly but in the absence of Cr(VI). Cells’ viability in culture, was evaluated 
by MTT assay every four days. The results, expressed as the ratio of final to initial cells’ viability are the mean ± SD 
of at least experiments carried out in triplicated. 
[Cr(VI)] 
(µM) 
Passage 
Number 
Cell 
Density 
(cell/cm2) 
Days 
Ratio of 
Final to 
Initial 
cells’ 
Viability  
2 
SD 
Value 
4 
SD 
Value 
8 
SD 
Value 
12 
SD 
Value 
16 
SD 
Value 
Control 8 20000 2,20 0,45 4,16 0,34 5,40 0,94 ND ND 7,36 0,89 
0.25 µM 8 20000 2,20 0,45 3,28 0,77 4,15 0,35 4,38 2,65 4,60 1,05 
0.5 µM 8 20000 2,20 0,45 2,97 3,09 3,57 0,72 3,38 0,53 3,06 1,25 
wo. Cr(VI) 8 20000 2,20 0,45 2,97 3,09 3,57 0,72 4,13 2,30 4,48 2,06 
Continuation 
[Cr(VI)] 
(µM) 
Passage 
Number 
Cell 
Density 
(cell/cm2) 
Days 
Ratio of 
Final to 
Initial cells’ 
Viability  
20 
SD 
Value 
24 
SD 
Value 
28 
SD 
Value 
32 
SD 
Value 
Control 8 20000 ND ND 8,87 0,99 ND ND 8,94 0,53 
0.25 µM 8 20000 4,63 0,34 4,76 0,38 4,53 0,48 4,73 0,42 
0.5 µM 8 20000 2,85 0,32 2,33 0,40 2,12 0,30 2,32 0,13 
wo. Cr(VI) 8 20000 4,31 0,30 4,74 0,30 4,86 0,59 5,29 0,15 
 
As illustrated (Figure 3.12), after 4 weeks, the viability of CBR cells exposed constantly 
one week to 0.5 µM Cr(VI)  (wo.Cr(VI) condition) overlapped the 32 days 0.25 µM Cr(VI) 
continuously exposed cells.  Simultaneously, 0.5 µM Cr(VI)-exposed cells confirm to be growth 
arrested after approximately three weeks in culture. The hypothesis that this 0.5 µM Cr(VI)- 
continuous exposed cells were mostly senescent was confirmed by the SA-β-gal assay (Figure 
3.13).  
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Figure 3.13: Representative images of the of CBR passage 8 cells with SA-β-gal senescent staining, day 32 in culture. 
Control (A), 0.25 µM (B, C), 0.5 µM (D, E, F) and wo.Cr(VI) (G, H), all magnified 100X. 
 
A 
B 
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As pointed up in Figure 3.12 (D-F), the extensive blue staining associated with SA-β-gal 
activity, portrayed by 0.5 µM Cr(VI)-exposed cells, revealed that cells had a senescent 
phenotype. The slight staining observed for 0.25 µM Cr(VI)-exposed cells, as well as for control 
cells, suggested that some of these cells were senescent possibly as result of confluence, more 
noticeable in the case of control cells (Figures 3.11 and 3.12 A). As to wo.Cr(VI) cells, the slight 
staining observed revealed that the senescent phenotype is reversible once the 0.5 µM Cr(VI)-
insult is removed  (Figure 3.12 G and H). 
Although hypoxia is known to delay the onset of senescence and in cancerous cells 
promote cell proliferation [Welford et al., 2006] recent work suggested that cycles of hypoxia 
and food deprivation may induce a state of stress-induced senescence [Choi et al., 2011]. 
Based on these studies, others experiments were carried out attempting to evaluate whether 
cycles of hypoxia followed by food deprivation would inhibit the senescence reverse observed 
in wo.Cr(VI) cultures once the Cr(VI)-insult was removed.  
For deprivation studies CBR cells, once constantly exposed during a week to 0.5 µM 
Cr(VI)-insult, had their medium changed only once a week instead of every two days. As to 
hypoxia, CBR cells once exposed a week to 0.5 µM Cr(VI)-insult, the multiwell plates were 
sealed with parafilm although the medium was changed  every two days. Combined 
experiments were also performed, i.e., one week hypoxia followed by another week of food 
deprivation. Controls were carried out simultaneously with Cr(VI) untreated CBR cells (Table 
3.14). 
 
Table 3.14: Four week-long experiments using CBR passage 9 and 10 cells exposed a week to 0.5 µM Cr(VI) and 
medium renewed with fresh 0.5 µM Cr(VI) medium every 2 days for a week. From week two onward, cells were 
submitted to cycles of hypoxia, deprivation or hypoxia and deprivation. Control experiments were performed in the 
absence of Cr(VI). 
 
Condition 
Passage 
Number 
Cell 
Density 
(cell/cm
2
) 
  
Week 
 1 2 3 4 
Hypoxia 
and 
Deprivation 
Cycles 
Control 9 20000 
Plating 
DMEM/F12 DMEM/F12 DMEM/F12 DMEM/F12 
Treated 9 20000 
0.5 µM 
Cr(VI) 
Hypoxia Deprivation Hypoxia 
Continuous 
Hypoxia 
and 
Continuous 
Deprivation  
Control 10 20000 DMEM/F12 DMEM/F12 DMEM/F12 DMEM/F12 
Hypoxia 10 20000 
0.5 µM 
Cr(VI) 
Hypoxia Hypoxia Hypoxia 
Deprivation 10 20000 
0.5 µM 
Cr(VI) 
Deprivation Deprivation Deprivation 
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As revealed by SA-β-gal activity staining images, the alternated cycles of hypoxia and 
deprivation could not inhibit the reversal senescence following removal of the Cr(VI)-insult 
(Figure 3.14).  
 
Figure 3.14: Representative images of the CBR passage 9 
cells with SA-β-gal senescent staining, day 32 in culture. 
Control (A), Cr(VI) exposure followed by alternated cycles 
of hypoxia and deprivation (B, C), all magnified 100X. 
 
 
 
 
As illustrated in Figure 3.15, cells submitted three weeks to hypoxia showed 
morphological similarities to 0.25 µM Cr(VI)-continuously exposed cells (Figure 3.11, B and C), 
while cells submitted for three weeks to deprivation appeared morphologically very similar to 
cells continuously exposed  0.5 µM Cr(VI) along 4 weeks in culture (Figure 3.11, D-F). 
Moreover, a one week Cr(VI)–insult followed by either hypoxia or deprivation induced 
extensive senescence. 
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Figure 3.15: Representative images of the morphology of 
CBR passage 9 cells, day 32 in culture.  Control (A), 
hypoxia exposed Cells (B) and deprivation exposed Cells 
(C), all magnified 100X. 
 
 
 
 
As illustrated (Figure 3.16) morphological changes correlated with senescent staining 
coinciding in both hypoxia and deprivation conditions.  
 
Figure 3.16: Representative images of the of CBR passage 
8 cells with SA-β-gal senescent staining, day 32 in culture. 
Control (A), hypoxia exposed Cells (B) and deprivation 
exposed Cells (C), all magnified 100X. 
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Figure 3.17: Representative effects of hypoxia, deprivation, and cycles of hypoxia and deprivation on CBR cells’ 
viability. Cells were exposed for a week to 0.5 µM Cr(VI) with medium changed every two days, followed by either 
hypoxia or deprivation , and alternative cycles of hypoxia and deprivation. The results are expressed as the ratio of 
final to initial cell viability evaluated by the MTT assay and represent the mean ± SD of three independent 
experiments. 
 
Table 3.15: Representative effects of hypoxia, deprivation, and cycles of hypoxia and deprivation on CBR cells’ 
viability. Cells were exposed for a week to 0.5 µM Cr(VI) with medium changed every two days, followed by either 
hypoxia or deprivation , and alternative cycles of hypoxia and deprivation. The results are expressed as the ratio of 
final to initial cell viability evaluated by the MTT assay and represent the mean ± SD of three independent 
experiments. 
 
Considering cell viability, morphological changes and senescent-staining, all these results 
can seem to be contradictory. Firstly, although cells exposed to hypoxia and deprivation cycles 
showed a cell viability arrest, the senescent-staining was not strong enough to warrant the 
consideration of this condition as capable of inducing and retaining senescence. 
 
Condition 
Passage 
Number 
Cell 
Density 
(cell/cm2) 
  Week 
 
Ratio of 
Final to 
Initial 
cells’ 
Viability  
1 
SD 
Value 
2 
SD 
Value 
3 
SD 
Value 
4 
SD 
Value 
Hypoxia and 
Deprivation 
Cycles 
Control 9 20000 4,28 1,25 6,32 0,31 7,70 1,87 9,14 0,56 
Treated 9 20000 2,61 0,51 4,13 0,91 4,55 0,88 4,75 1,23 
Continuous 
Hypoxia and 
Continuous 
Deprivation 
Control 10 20000 3,98 0,95 6,05 0,15 9,34 0,60 11,22 0,40 
Hypoxia 10 20000 2,94 0,91 4,07 0,51 7,53 0,40 7,70 0,53 
Deprivation 10 20000 2,94 0,91 4,13 0,21 4,73 0,28 6,28 0,34 
87 
 
It can be proposed that this arrest was not due to entering the state of senescence but 
related to a lag phase, being the cells in the process of adaptation to new conditions, having 
never reached a exponential growth phase, that would be reflected on a cell viability increase, 
due to constant change of conditions. 
At the same time, constant hypoxia and deprivation conditions showed staining and 
morphology changes similar to 0.25 and 0.5 µM Cr(VI) continuous exposure, considered the 
best conditions for senescence. This was not totally correlated in terms of cell viability as there 
is no significant long-term viability ratio stagnation. However, it can be observed that between 
the third and fourth weeks of the experiment, hypoxia-treated cells did not show a significant 
increase in viability ratio (Δ ratio = 0.17) while between the second and third weeks, 
deprivation-treated cells showed little increase in viability ratio (Δ ratio = 0.60). 
This data, correlated with the senescent staining and morphology changes, suggest that 
further weeks of experiment would be needed to obtain a conclusive result. Meanwhile, these 
results suggest that, possibly, the senescence-inducing pathways activated by hypoxia and 
deprivation treatment would be different from the ones activated by Cr(VI) exposure only. 
 
 
3.3.3. IMMUNOCYTOCHEMICAL CHARACTERIZATION OF SENESCENT 
FIBROBLASTS 
Immunocytochemistry analysis was used to characterize CBR passage 9 fibroblasts 
continuously exposed to 0.25 and 0.5 µM Cr(VI) for 6 weeks. As expected, both control and 
0.25 and 0.5 µM continuously exposed cells, stained positive for vimentin. The ubiquitous 
distribution of this protein confirmed the fibroblast nature of these cells (Figure 3.18).  
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Figure 3.18: Representative images of fibroblasts, CBR passage 9 exposed to Cr(VI), immunocytochemical staining. 
Cells had been previously plated on top of microscopic slides for staining later on for vimentin as described in 
Materials and Methods. Control (A), and 0.25 µM Cr(VI) (B), amplified 100x (A, B). Orange staining: Vimentin. Blue 
staining: Nuclei. 
 
However, as revealed in Figures 3.19 and 3.20, the CBR cultures were not homogeneous 
since three sub-populations could be clearly identified: (i) a sub-population composed by cells 
with large nucleus; (ii) another sub-population composed of cells with small nuclei; (iii) a sub-
population composed of cells with elongated nucleus. Positive staining for, α smooth muscle 
actin (α–SMA), a biomarker of mesenchymal and myofibroblasts cells, was particularly 
abundant in cultures exposed to Cr(VI)  (Figures 3.19 and 3.20). In fact, the abundance of cells 
with elongated nucleus increased as Cr(VI) concentration increased, while the abundance of 
the other populations decreased, particularly the small nucleus cells. The morphology of the 
cells with elongated nucleus revealed they are mesenchymal-like fibroblasts and not 
myofibroblast-like cells (small nucleus). It appears that mesenchymal-like fibroblasts are more 
resistant to Cr(VI) exposure than myofibroblasts.  
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Figure 3.19: Representative images of fibroblasts, CBR 
passage 9 exposed to Cr(VI), immunocytochemical 
staining for α-SMA. CBR passage 9 cells had been 
previously plated on top of microscopic slides for staining 
later on for α-SMA as described in Materials and 
Methods. Control (A), 0.25 µM Cr(VI) (B) and 0.5 µM 
Cr(VI) (C), magnified 100x (A, C) and 200x (B). Orange 
staining: α-SMA. Blue staining: Nuclei. Grey staining: 
Cytoplasm. 
 
 
Regarding the staining with MNF-116, control cells showed a mild staining; however it 
was not strong enough to justify a positive staining (Figure 3.20). As to Cr(VI) exposed cells, the 
negative MNF-116 revealed an apparent absence of epithelial cells, ruling out a EMT under 
Cr(VI) stress. However, the positive staining of very few cells for E-Cadherin in cultures 
exposed to 0.5 µM Cr(VI) may suggest the formation of myoepithelial cells through a 
mesenchymal to epithelial transition (MET) (Figure 3.21).   
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Figure 3.20: Representative images of fibroblasts, CBR passage 9 exposed to Cr(VI), immunocytochemical staining. 
CBR passage 9 cells had been previously plated on top of microscopic slides for staining later on for MNF-116 as 
described in Materials and Methods. Control (A), 0.25 µM Cr(VI) (B, C) and 0.5 µM Cr(VI) (D). Magnification: 100x (A, 
B, D) and 200x (C). Dark Blue staining: MNF-116. Blue staining: Nuclei. Grey staining: Cytoplasm. 
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Figure 3.21: Representative images of fibroblasts, CBR passage 9 exposed to Cr(VI), immunocytochemical staining  
for E-Cadherin. CBR passage 9 cells had been previously plated on top of microscopic slides for staining later on for 
E-Cadherin as described in Materials and Methods. Control (A), 0.25 µM Cr(VI) (B) and 0.5 µM Cr(VI) (C, D), 
magnified 100x (A, B, C) and 200x (D). Pink staining: E-Cadherin. Blue staining: Nuclei. Grey staining: Cytoplasm. 
 
Finally, the Cr(VI)-induced senescent-phenotype of CBR, passage 9, cells could be 
characterized as a predominant mesenchymal population, with small expression of α-SMA and 
cytokeratins. These two protein’ small expression could be related with the morphological 
changes in the cell in terms of nuclei and cell form, as they lost their previously organized state 
to a rounder-shape. 
While there is the possibility of the senescent fibroblasts to be associated with a MET, 
through the results of E-Cadherin staining, it should be noted that further studies must be 
done in order to really assess the depth of the occurring changes, although the possibility of a 
MET could explain the effect of senescent fibroblasts on epithelial cells growth and 
disorganization in co-culture 
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3.4. CO-CULTURES: THE EFFECTS OF SENESCENT FIBROBLASTS ON BEAS-2B 
CELLS PROLIFERATION 
The effects of Cr(VI)-senescent fibroblasts on bronchial epithelial cells prolidferation 
and morphology were studied using the co-culture model of Chanson and collaborators 
[Wiszniewski et al., 2006]. To this end, E7A passage 4 fibroblasts were first exposed to either 
0.25 or 0.5 µM Cr(VI), according to Table 3.12 (section 3.3), as these exposure regimens would 
guarantee that senescence would be achieved within 4 weeks of continuously exposure to 
Cr(VI). These 4 weeks treated fibroblasts were used as feeder layers in the co-culture 
experiments with BEAS-2B passage 5 cells on the top of gelatine coated transwells (Table 
3.16).  
 
Table 3.16: Co-Culture Experiments using either E7A passage 4 normal or Cr(VI)-senescent fibroblasts and BEAS-2B 
passage 5 In all experiments with Cr(VI) (added 3 days after BEAS-2B cells plating), the medium was renewed every 
three days along time in culture as described in Materials and Methods. 
  
Fibroblasts E7A 
Passage 4 
Cell Density 
20000 cell/cm2 
  
  
Senescent  
  
Control 
0.25 µM 
Cr(VI) 
0.5 µM Cr(VI) 
BEAS-2B Control Yes Yes Yes 
 Passage 5 
0.25 µM 
Cr(VI) 
Yes Yes   
 Cell Density 
45000 cell/cm2 
0.5 µM Cr(VI) Yes   Yes 
 
As observed in Figure 3.22, within the first 24 hours co-cultures of BEAS-2B with 0.5 µM 
Cr(VI)-induced-senescent fibroblasts were more confluent than co-cultures of BEAS-2B with 
normal fibroblasts.  However, as revealed in Figure 3.23 no additional changes were observed 
when the co-cultures were performed in presence of Cr(VI). 
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Figure 3.22: Representative images of the morphology of 
BEAS-2B passage 5 cells, day 1 in co-culture.  With Control 
Fibroblasts (A), 0.25 µM Cr(VI)-Induced Senescent 
Fibroblasts (B) and 0.5 µM Cr(VI)-Induced Senescent 
Fibroblasts (C), all magnified 100X. 
 
 
 
 
 
Prolonged co-cultivation showed no additional changes even in presence of Cr(VI) (Figure 
3.23). This is due to the fact that BEAS-2B are immortalized cells and therefore their growth 
rate is greater than normal bronchial epithelial cells, leading to a quicker confluency and 
therefore a smaller Cr(VI) concentration per cell, resulting in a much smaller effect. 
These results were then inconclusive regarding the effect of senescent fibroblasts in 
bronchial epithelial cells proliferation, whether in the presence or absence of Cr(VI), mainly 
due to the initial epithelial cell density 
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Figure 3.23: Representative images of the morphology of 
BEAS-2B passage 5 cells, day 4 in co-culture, 1 day after 
addition of Cr(VI). With Control Fibroblasts and in 
absence of Cr(VI) (A), with Control Fibroblasts and in the 
presence of 0.25 µM Cr(VI) (B), with Control Fibroblasts 
and in the presence of 0.5 µM Cr(VI) (C), with 0.25 µM 
Cr(VI)-Induced Senescent Fibroblasts and in absence of 
Cr(VI) (D), with 0.25 µM Cr(VI)-Induced Senescent 
Fibroblasts and in the presence of 0.25 µM Cr(VI) (E), with 
0.5 µM Cr(VI)-Induced Senescent Fibroblasts and in the 
absence of Cr(VI) (F) and with 0.5 µM Cr(VI)-Induced 
Senescent Fibroblasts and in the presence of 0.5 µM 
Cr(VI) (G), all magnified 100X. 
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In the concluding and final remarks of this work it is possible to focus that, effectively, 
cell culture techniques are a very useful tool of research, as most of the results were based on 
these techniques. 
Firstly, primary cultures of both bronchial fibroblasts and bronchial epithelial cells were 
obtained, albeit the degree of success cannot be considered 100% due to problems already 
referred in sections 3.1 and 3.2. Therefore, in future projects, related with the use of primary 
cultures as an end result, the exact methodology for this aim should be perfected. 
In this work it was possible to observe that Cr(VI) is able to induce changes in bronchial 
fibroblasts associated with senescence, being confirmed by the expression of SA-βgal. 
Considering this, one great result was the establishment of a model of exposure to Cr(VI) that 
allows bronchial fibroblasts to express a stable senescent phenotype, being able to be 
maintained up to 4 weeks in culture afterwards. This model requires a cell density of 20000 
cells/cm2, with 0.25 and 0.5 µM Cr(VI) addition every two days, for 4 weeks, as detailed on 
section 3.3.2. 
Also, regarding the effect of Cr(VI) and induction of senescent, it was observed that both 
deprivation and hypoxia conditions, after 0.5 µM Cr(VI) exposure, were able to induce 
senescence on bronchial fibroblasts. 
Still regarding senescent fibroblasts, it was shown that, in terms of 
immunocytochemistry, the primary cultures had several populations initially but only one 
strived in Cr(VI) exposure conditions, leading to a predominantly mesenchymal-like phenotype, 
with elongated nuclei, that characterized the 0.5 µM Cr(VI) senescent cells, as seen on section 
3.3.3. 
Although promising, these results did not answer any questions regarding the 
mechanisms by which senescence was attained in these fibroblasts, although it was not the 
focus of this work. Therefore, for this aim, further studies are required, focusing mainly on 
DNA damage response and ROS formation, as well as identifying which, between pRb and p53, 
if not both pathways, leads to the obtained senescent state in bronchial fibroblasts. 
Also, further characterization of these senescent fibroblasts should be done, namely their 
metabolism, e.g. answering if glycolysis rate increases, as well as oxidative phosphorylation 
rate, as well as secreted factores, comparing this phenotype to the secretory senescent 
phenotype described in literature. 
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As for the final aim of the work, co-cultures have been shown to be a viable way to mimic 
in vivo situations, considering the existence of a supportive and dynamic layer beneath 
epithelial cells. 
Yet, for the proposed objective of observing if there was any change in proliferation and 
differentiation of bronchial epithelial cells, in the presence of senescent fibroblasts and Cr(VI), 
the results were inconclusive. This was due mainly to the cell type used, as BEAS-2B are an 
immortalized cell line, being used in substitution of bronchial epithelial cells primary culture, 
have a greater proliferation rate. This, associated with the initial cell density used, based on 
literature considering the use of cell co-culture, resulted in the main flaws of the final work 
section (section 3.4). 
Therefore, to realize the effects of senescent fibroblasts on bronchial epithelial cells in 
co-culture, closely to an in vivo situation, it is essential that, first of all, primary cultures of 
epithelial cells are successfully obtained and, most importantly, are able to be sub-cultured, 
using a correct protocol.  
It should be also noted, that the decisions of BEAS-2B usage in the co-culture section and 
regarding the cell density used, were greatly influenced by the amount of time left until the 
official deadline for the master’s thesis conclusion. 
Considering that the work was mostly based on literature, without any previous results 
regarding primary cell culture and senescence studies on fibroblasts that could be related to 
this project, it can be said that the project was fairly ambitious for a one year master’s thesis. 
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